<!DOCTYPE html><html class="" lang="en"><head>
<!-- REQUIRED META INFORMATION -->
<meta charset="UTF-8">
<meta http-equiv="X-UA-Compatible" content="IE=edge,chrome=1">
<meta name="viewport" content="width=device-width, initial-scale=1">

<meta name="DCTERMS:contentOwner" content="TNeville">
<meta name="DCTERMS:contentOffice" content="DCRDP:ODP:OMP">

<meta name="DCTERMS:coder" content="^ORDP Webmaster">
<meta name="DCTERMS:coderOffice" content="DCRDP:ODEPPIN:OPPS">

<meta name="description" content="4.00-Cardiovascular-Adult">
<meta name="DCTERMS:dateCertified" content="2019-11-25">
 
<!-- DOCUMENT TITLE -->
<title>4.00 - Cardiovascular - Adult | Disability | SSA</title>
 
<!-- STYLES -->
<link rel="stylesheet" href="/framework/css/ssa.firefly.css">

<!-- SCRIPTS -->
<script type="text/javascript" async="" src="https://www.googletagmanager.com/gtm.js?id=GTM-TL5XBDT&amp;gtm=4e5b50"></script><script async="" src="https://www.googletagmanager.com/gtm.js?id=GTM-5GQXH7Q"></script><script src="/framework/js/ssa.firefly.head.js"></script>


<script>(window.BOOMR_mq=window.BOOMR_mq||[]).push(["addVar",{"rua.upush":"false","rua.cpush":"false","rua.upre":"false","rua.cpre":"false","rua.uprl":"false","rua.cprl":"false","rua.cprf":"false","rua.trans":"","rua.cook":"false","rua.ims":"false","rua.ufprl":"false","rua.cfprl":"false","rua.isuxp":"false","rua.texp":"norulematch","rua.ceh":"false","rua.ueh":"false","rua.ieh.st":"0"}]);</script>
                              <script>!function(e){var n="https://s.go-mpulse.net/boomerang/";if("False"=="True")e.BOOMR_config=e.BOOMR_config||{},e.BOOMR_config.PageParams=e.BOOMR_config.PageParams||{},e.BOOMR_config.PageParams.pci=!0,n="https://s2.go-mpulse.net/boomerang/";if(window.BOOMR_API_key="LERZW-HECFS-R8H4E-23UQ7-ERMQB",function(){function e(){if(!o){var e=document.createElement("script");e.id="boomr-scr-as",e.src=window.BOOMR.url,e.async=!0,i.parentNode.appendChild(e),o=!0}}function t(e){o=!0;var n,t,a,r,d=document,O=window;if(window.BOOMR.snippetMethod=e?"if":"i",t=function(e,n){var t=d.createElement("script");t.id=n||"boomr-if-as",t.src=window.BOOMR.url,BOOMR_lstart=(new Date).getTime(),e=e||d.body,e.appendChild(t)},!window.addEventListener&&window.attachEvent&&navigator.userAgent.match(/MSIE [67]\./))return window.BOOMR.snippetMethod="s",void t(i.parentNode,"boomr-async");a=document.createElement("IFRAME"),a.src="about:blank",a.title="",a.role="presentation",a.loading="eager",r=(a.frameElement||a).style,r.width=0,r.height=0,r.border=0,r.display="none",i.parentNode.appendChild(a);try{O=a.contentWindow,d=O.document.open()}catch(_){n=document.domain,a.src="javascript:var d=document.open();d.domain='"+n+"';void(0);",O=a.contentWindow,d=O.document.open()}if(n)d._boomrl=function(){this.domain=n,t()},d.write("<bo"+"dy onload='document._boomrl();'>");else if(O._boomrl=function(){t()},O.addEventListener)O.addEventListener("load",O._boomrl,!1);else if(O.attachEvent)O.attachEvent("onload",O._boomrl);d.close()}function a(e){window.BOOMR_onload=e&&e.timeStamp||(new Date).getTime()}if(!window.BOOMR||!window.BOOMR.version&&!window.BOOMR.snippetExecuted){window.BOOMR=window.BOOMR||{},window.BOOMR.snippetStart=(new Date).getTime(),window.BOOMR.snippetExecuted=!0,window.BOOMR.snippetVersion=12,window.BOOMR.url=n+"LERZW-HECFS-R8H4E-23UQ7-ERMQB";var i=document.currentScript||document.getElementsByTagName("script")[0],o=!1,r=document.createElement("link");if(r.relList&&"function"==typeof r.relList.supports&&r.relList.supports("preload")&&"as"in r)window.BOOMR.snippetMethod="p",r.href=window.BOOMR.url,r.rel="preload",r.as="script",r.addEventListener("load",e),r.addEventListener("error",function(){t(!0)}),setTimeout(function(){if(!o)t(!0)},3e3),BOOMR_lstart=(new Date).getTime(),i.parentNode.appendChild(r);else t(!1);if(window.addEventListener)window.addEventListener("load",a,!1);else if(window.attachEvent)window.attachEvent("onload",a)}}(),"".length>0)if(e&&"performance"in e&&e.performance&&"function"==typeof e.performance.setResourceTimingBufferSize)e.performance.setResourceTimingBufferSize();!function(){if(BOOMR=e.BOOMR||{},BOOMR.plugins=BOOMR.plugins||{},!BOOMR.plugins.AK){var n=""=="true"?1:0,t="cookiepresent",a="im6jsaqxzhbro2ioayuq-f-b590119c7-clientnsv4-s.akamaihd.net",i="false"=="true"?2:1,o={"ak.v":"39","ak.cp":"1204614","ak.ai":parseInt("728289",10),"ak.ol":"0","ak.cr":20,"ak.ipv":4,"ak.proto":"h3","ak.rid":"ca15b94","ak.r":39734,"ak.a2":n,"ak.m":"dsca","ak.n":"essl","ak.bpcip":"67.60.153.0","ak.cport":57631,"ak.gh":"23.201.194.23","ak.quicv":"0x00000001","ak.tlsv":"tls1.3","ak.0rtt":"","ak.0rtt.ed":"","ak.csrc":"-","ak.acc":"","ak.t":"1762526761","ak.ak":"hOBiQwZUYzCg5VSAfCLimQ==IrtcAFZWirdoHPPUtn7ebGQTw5dWNH9owrnKZFPlSZ2q3q5oFCEWatgvey1yEntzuI48NifWWiSD2OFmBNgEp4uQ9imPuelB1qI4Yl+yZqFRuFy/sb29mj/z6+wB4Uw2c05FESyapKMdr6EhQdzAMBrdzl93WpEm7VmmMtocbfheU/RHzG5s9IOlU12Oi+tLa6XMwwWe4ZgVcK6XqqGL8D3/HnGKZEHv/pm95B2WVIGyKpn0gVg3qhpFTaSMEyiZblXYRejW1l4ch/uo/yMJCD8ltw0KFSx6CoG0Lv7SOrAsAbbRULU6TjdajHrBneHhUh9AuToLzhIgI4UJicNa2d0d6hqTopd3wuEvsOGiC6WARDEoPvKVDUcqMniGQh4gvKOHLNZgKI7ssNcWnWALDMCwkBwci7Zbf7S1HCHMOj8=","ak.pv":"120","ak.dpoabenc":"","ak.tf":i};if(""!==t)o["ak.ruds"]=t;var r={i:!1,av:function(n){var t="http.initiator";if(n&&(!n[t]||"spa_hard"===n[t]))o["ak.feo"]=void 0!==e.aFeoApplied?1:0,BOOMR.addVar(o)},rv:function(){var e=["ak.bpcip","ak.cport","ak.cr","ak.csrc","ak.gh","ak.ipv","ak.m","ak.n","ak.ol","ak.proto","ak.quicv","ak.tlsv","ak.0rtt","ak.0rtt.ed","ak.r","ak.acc","ak.t","ak.tf"];BOOMR.removeVar(e)}};BOOMR.plugins.AK={akVars:o,akDNSPreFetchDomain:a,init:function(){if(!r.i){var e=BOOMR.subscribe;e("before_beacon",r.av,null,null),e("onbeacon",r.rv,null,null),r.i=!0}return this},is_complete:function(){return!0}}}}()}(window);</script><link href="https://s.go-mpulse.net/boomerang/LERZW-HECFS-R8H4E-23UQ7-ERMQB" rel="preload" as="script"><style>@font-face{font-family:"Public Sans Web";src:url(https://www.ssa.gov/legacy/components/dist/assets/fonts/public-sans/PublicSans-Light.woff2) format("woff2"),url(https://www.ssa.gov/legacy/components/dist/assets/fonts/public-sans/PublicSans-Light.woff) format("woff"),url(https://www.ssa.gov/legacy/components/dist/assets/fonts/public-sans/PublicSans-Light.ttf) format("truetype");font-weight:300;font-style:normal;font-display:swap}@font-face{font-family:"Public Sans Web";src:url(https://www.ssa.gov/legacy/components/dist/assets/fonts/public-sans/PublicSans-Regular.woff2) format("woff2"),url(https://www.ssa.gov/legacy/components/dist/assets/fonts/public-sans/PublicSans-Regular.woff) format("woff"),url(https://www.ssa.gov/legacy/components/dist/assets/fonts/public-sans/PublicSans-Regular.ttf) format("truetype");font-weight:400;font-style:normal;font-display:swap}@font-face{font-family:"Public Sans Web";src:url(https://www.ssa.gov/legacy/components/dist/assets/fonts/public-sans/PublicSans-SemiBold.woff2) format("woff2"),url(https://www.ssa.gov/legacy/components/dist/assets/fonts/public-sans/PublicSans-SemiBold.woff) format("woff"),url(https://www.ssa.gov/legacy/components/dist/assets/fonts/public-sans/PublicSans-SemiBold.ttf) format("truetype");font-weight:600;font-style:normal;font-display:swap}@font-face{font-family:"Public Sans Web";src:url(https://www.ssa.gov/legacy/components/dist/assets/fonts/public-sans/PublicSans-Bold.woff2) format("woff2"),url(https://www.ssa.gov/legacy/components/dist/assets/fonts/public-sans/PublicSans-Bold.woff) format("woff"),url(https://www.ssa.gov/legacy/components/dist/assets/fonts/public-sans/PublicSans-Bold.ttf) format("truetype");font-weight:700;font-style:normal;font-display:swap}@font-face{font-family:"Public Sans Web";src:url(https://www.ssa.gov/legacy/components/dist/assets/fonts/public-sans/PublicSans-ExtraBold.woff2) format("woff2"),url(https://www.ssa.gov/legacy/components/dist/assets/fonts/public-sans/PublicSans-ExtraBold.woff) format("woff"),url(https://www.ssa.gov/legacy/components/dist/assets/fonts/public-sans/PublicSans-ExtraBold.ttf) format("truetype");font-weight:800;font-style:normal;font-display:swap}</style><meta property="og:site_name" content="Social Security"><meta property="og:type" content="website"><meta property="og:url" content="https://www.ssa.gov/disability/professionals/bluebook/4.00-Cardiovascular-Adult.htm"><meta property="og:title" content="4.00 - Cardiovascular - Adult | Disability | SSA"><meta property="og:description" content="4.00-Cardiovascular-Adult"><meta property="og:image:url" content="https://www.ssa.gov/themes/custom/ssa_core/logo.svg"><meta property="og:image:secure_url" content="https://www.ssa.gov/themes/custom/ssa_core/logo.svg"><meta property="og:image:alt" content="U.S. Social Security Administration"><meta property="og:locale" content="en_US"><meta property="og:locale:alternate" content="es_ES"><script id="boomr-scr-as" src="https://s.go-mpulse.net/boomerang/LERZW-HECFS-R8H4E-23UQ7-ERMQB" async=""></script></head>

<body style="margin: 0px;">
  <!-- BANNER -->
  <aside class="accessibility" id="accessibility"><a href="#content" id="skip-navigation">Skip to main content</a></aside>
<!-- WCMS SITE ALERT (EMERGENCY) -->
<div class="wsa" aria-label="Site Alert" data-type="emergency">
  <div class="wsag">
    <svg focusable="false" height="26" width="26" viewBox="0 0 20 20" aria-hidden="true">
      <path fill="#FFFFFF" fill-rule="evenodd" stroke-width="0" d="M10.8,15h-1.7v-1.7h1.7v1.7ZM10.8,11.7h-1.7v-4.9h1.7v4.9Z" vector-effect="non-scaling-stroke"></path>
      <path fill="#1C1D1F" fill-rule="evenodd" stroke-width="0" d="M.8,17.5h18.3L10,1.7.8,17.5ZM10.8,15h-1.7v-1.7h1.7v1.7ZM10.8,11.7h-1.7v-4.9h1.7v4.9h0Z" vector-effect="non-scaling-stroke"></path>
    </svg>
    <div>
      <a href="/myaccount/"><u>Social Security and SSI Payments will Continue during the Government Shutdown.  Visit my Social Security for Online Services.</u></a>
    </div>
  </div>
</div>
<!-- WCMS SITE ALERT (INFORMATION) -->
<div class="wsa" aria-label="Site Alert" data-type="information">
  <div class="wsag">
    <svg focusable="false" height="26" width="26" viewBox="0 0 20 20" aria-hidden="true">
      <path fill="#1C1D1F" fill-rule="evenodd" stroke-width="0" d="M10,1.7C5.4,1.7,1.7,5.4,1.7,10s3.7,8.3,8.3,8.3,8.3-3.7,8.3-8.3S14.6,1.7,10,1.7ZM9.2,7.5v-1.7h1.7v1.7h-1.7ZM9.2,9.2v5h1.7v-5h-1.7Z" vector-effect="non-scaling-stroke"></path>
      <path fill="#FFFFFF" fill-rule="evenodd" stroke-width="0" d="M10.8,7.5h-1.7v-1.7h1.7v1.7Z" vector-effect="non-scaling-stroke"></path>
      <path fill="#FFFFFF" fill-rule="evenodd" stroke-width="0" d="M10.8,14.2h-1.7v-5h1.7v5Z" vector-effect="non-scaling-stroke"></path>
    </svg>
    <div>
      <a href="https://www.ssa.gov/manage-benefits/get-benefit-letter"><u>Get a benefit verification letter.</u></a>
    </div>
  </div>
</div>
<ssa-header class="print-dn"></ssa-header><script src="https://www.ssa.gov/legacy/components/dist/ssa-header.js"></script>
  <!-- MAIN CONTENT -->
  <main class="content" id="content" role="main">
    <!-- TITLE BAR -->
    <section class="bg-ivory-200">
      <!-- WRAPPER -->
      <div class="py2 wrapper">
        <h2 class="fw4 ma0" id="Top">Medical/Professional Relations</h2></div>

    </section>

    <!-- WRAPPER -->
    <section class="wrapper">
    
    <!--GRID-->
<div class="grid">
	
<!-- FIRST COLUMN -->
<article class="cell w-100 m-w-100">
	
<!-- BREADCRUMBS -->
<nav class="breadcrumbs fs1" aria-label="Breadcrumbs">
  <ol>
    <li><a href="https://www.ssa.gov">SSA Home</a></li>
	<li><a href="https://www.ssa.gov/disability">Disability</a></li>
	<li><a href="../index.htm">Medical/Professional Relations</a></li>
	<li><a href="index.htm">Disability Evaluation Under Social Security</a></li>
	<li><a href="AdultListings.htm">Listing of Impairments - Adult Listings (Part A)</a></li> 
    <li aria-current="page">4.00 Cardiovascular System - Adult </li>
  </ol>
</nav>
</article><!--END FIRST COLUMN-->

<!-- FIRST COLUMN -->
<article class="cell w-100 m-w-20">


<p class="js-toggle"><a href="AdultListings.htm">Adult Listings (Part A)</a></p>
<p class="js-toggle"><a href="ChildhoodListings.htm">Childhood Listings (Part B)</a></p>
<p class="js-toggle"><a href="general-info.htm">General Information</a></p>
<p class="js-toggle"><a href="evidentiary.htm">Evidentiary Requirements</a></p>
<p class="js-toggle"><a href="listing-impairments.htm">Listing of Impairments (overview) </a></p>

<p class="js-toggle"><a href="revisions-rules.html">Revisions to Rules Regarding the Evaluation of Medical Evidence</a></p>
                          </article><!-- END FIRST COLUMN-->

<!--SECOND COLUMN-->
<article class="cell w-100 m-w-80">

     <h2><span><b> Disability Evaluation Under Social Security<br>
        <span>(Blue Book- October 2008)</span><br>
        <br>
        4.00 Cardiovascular System - Adult<br>
        &nbsp;</b></span></h2>


                            <!--GRID-->
					<div class="grid">

                         <!--FIRST INNER COLUMN-->
					<article class="cell w-100 m-w-20">

<u><b>Section</b></u><br><br>
      <p align="left"> 
               <a href="#4_01"><b>4.01</b><br>
                Category of&nbsp;<br>
              Impairments,<br>
              Cardiovascular<br>
              System </a><br>
              <br>
              <a href="#4_02"><strong>4.02</strong><br>
              Chronic<br>
              heart&nbsp;failure</a><br>
              <a href="#4_04"><br>
              <b>4.04</b><br>
              Ischemic<br>
              heart disease </a><br>
              <br>
              <a href="#4_05" title=" 4.05 Recurrent arrhythmias"> <b>4.05</b><br>
              Recurrent<br>
              arrhythmias</a><br>
              <br>
              <a href="#4_06" title=" 4.06 Symptomatic congenital heart disease"><b>4.06</b><br>
              Symptomatic<br>
              congenital<br>
              heart&nbsp;disease</a><a href="#4_09" title=" 4.09 Cardiac transplantation"> <br>
              <br>
              <b>4.09</b><br>
              Heart&nbsp;<br>
              transplant</a><br>
              <br>
              <a href="#4_10" title=" 4.10 Aneurysm of aorta or major branches"> <b>4.10</b><br>
             Aneurysm of<br>
              aorta&nbsp;or<br>
              major branches</a><br>
              <br>
              <a href="#4_11" title=" 4.11 Chronic venous insufficiency"> <b>4.11</b><br>
              Chronic&nbsp;venous<br>
              insufficiency</a><br>
              <br>
              <a href="#4_12" title=" 4.12 Peripheral arterial disease"><b>4.12</b>
Peripheral arterial disease
</a>
                            </p></article><!--END FIRST INNER COLUMN-->

							<!--SECOND inner COLUMN-->
							<article class="cell w-100 m-w-80">
                            
 <p id="4_00"></p><u><b>4.00 Cardiovascular System</b></u><p></p>
 <p id="4_00A">A. General</p>
            <p id="4_00A1">1. <em>What do we mean by a cardiovascular impairment?</em></p>
            <p id="4_00A1a">a. We mean any disorder that affects the proper functioning of the heart or the circulatory system (that is,  arteries, veins, capillaries, and the lymphatic drainage). The disorder can be  congenital or acquired.</p>
            <p id="4_00A1b">b. Cardiovascular impairment results from one or more of four consequences of heart disease:</p>
            <p id="4_00A1bi">(i) Chronic heart failure or ventricular dysfunction.</p>
            <p id="4_00A1bii">(ii) Discomfort or pain due to myocardial ischemia, with or without necrosis of heart muscle.</p>
            <p id="4_00A1biii">(iii) Syncope, or near syncope, due to inadequate cerebral perfusion from any cardiac cause, such as  obstruction of flow or disturbance in rhythm or conduction resulting in  inadequate cardiac output.</p>
            <p id="4_00A1biv">(iv) Central cyanosis due to right-to-left shunt, reduced oxygen concentration in the arterial blood, or  pulmonary vascular disease.</p>
            <p id="4_00A1c">c. Disorders of the veins or arteries (for example, obstruction, rupture, or aneurysm) may cause impairments of the lower extremities (peripheral vascular disease), 
                the central nervous  system, the eyes, the kidneys, and other organs. 
                We will evaluate peripheral vascular disease under <a href="#4_11" title="Section 4.11">4.11</a> or <a href="#4_12" title="Section 4.12">4.12</a> and impairments of another body system(s)under the listings for that body system(s).</p>
            <p id="4_00A2">2. <em>What do we consider in evaluating cardiovascular impairments?</em> The listings in this section  describe cardiovascular impairments based on symptoms, signs, laboratory findings, response to a regimen of prescribed treatment, and functional  limitations.</p>
            <p id="4_00A3">3. <em>What do the following terms or phrases mean in these listings?</em> </p>
            <p id="4_00A3a">a. <em>Medical consultant</em> is an individual defined in §§ <a href="https://www.ssa.gov/OP_Home/cfr20/404/404-1616.htm#a" target="_blank" title="Code of Federal Regulations section 404.1616 - Subsection a">404.1616(a)</a> and <a href="https://www.ssa.gov/OP_Home/cfr20/416/416-1016.htm#a" target="_blank" title="Code of Federal Regulations section 416.1016 - Subsection a">416.1016(a)</a>. 
                This term does not include medical sources who provide consultative examinations for us. We use the abbreviation “MC” throughout this section to designate a medical consultant.</p>
            <p id="4_00A3b">b. <em>Persistent</em> means that the longitudinal clinical record shows that, with few exceptions, the  required finding(s) has been present, or is expected to be present, for a continuous period of at least 12 months, such that a pattern of continuing  severity is established.</p>
            <p id="4_00A3c">c. <em>Recurrent</em> means that the longitudinal clinical record shows that, within a consecutive 12-month  period, the finding(s) occurs at least three times, with intervening periods of  improvement of sufficient duration that it is clear that separate events are  involved.</p>
            <p id="4_00A3d">d. <em>Appropriate medically acceptable imaging</em> means that the technique used is the proper one to  evaluate and diagnose the impairment and is commonly recognized as accurate for  assessing the cited finding.</p>
            <p id="4_00A3e">e. <em>A consecutive 12-month period</em> means a period of 12 consecutive months, all or part of  which must occur within the period we are considering in connection with an  application or continuing disability review.</p>
            <p id="4_00A3f">f. <em>Uncontrolled</em> means the impairment does not adequately respond to standard prescribed medical  treatment.</p>
            <p id="4_00B"><strong>B.</strong> <em>Documenting Cardiovascular Impairment</em> </p>
            <p id="4_00B1">1. <em>What basic documentation do we need?</em> We need sufficiently detailed reports of  history, physical examinations, laboratory studies, and any prescribed  treatment and response to allow us to assess the severity and duration of your  cardiovascular impairment. A longitudinal clinical record covering a period of  not less than 3 months of observations and treatment is usually necessary,  unless we can make a determination or decision based on the current evidence.</p>
            <p id="4_00B2">2. <em>Why is a longitudinal clinical record important?</em> We will usually need a longitudinal clinical record to assess the severity and expected duration of your impairment(s). If  you have a listing-level impairment, you probably will have received medically  prescribed treatment. Whenever there is evidence of such treatment, your  longitudinal clinical record should include a description of the ongoing  management and evaluation provided by your treating or other medical source. It  should also include your response to this medical management, as well as  information about the nature and severity of your impairment. The record will  provide us with information on your functional status over an extended period  of time and show whether your ability to function is improving, worsening, or  unchanging.</p>
            <p id="4_00B3">3. <em>What if you have not received ongoing medical treatment?</em></p>
            <p id="4_00B3a">a. You may not have received ongoing treatment or have an ongoing relationship with the medical community despite the existence of a severe impairment(s). In this situation, we will  base our evaluation on the current objective medical evidence and the other  evidence we have. If you do not receive treatment, you cannot show an impairment  that meets the criteria of most of these listings. However, we may find you  disabled because you have another impairment(s) that in combination with your  cardiovascular impairment medically equals the severity of a listed impairment  or based on consideration of your residual functional capacity and age,  education, and work experience.</p>
            <p id="4_00B3b">b. Unless we can decide your  claim favorably on the basis of the current evidence, a longitudinal record is still important. In rare instances where there is no or insufficient  longitudinal evidence, we may purchase a consultative examination(s) to help us  establish the severity and duration of your impairment.</p>
            <p id="4_00B4">4. <em>When will we wait  before we ask for more evidence?</em></p>
            <p id="4_00B4a">a. We will wait when we have  information showing that your impairment is not yet stable and the expected change in your impairment might affect our determination or decision. In these  situations, we need to wait to properly evaluate the severity and duration of  your impairment during a stable period. Examples of when we might wait are:</p>
            <p id="4_00B4ai">(i) If you have had a recent  acute event; for example, a myocardial infarction (heart attack).</p>
            <p id="4_00B4aii">(ii) If you have recently  had a corrective cardiac procedure; for example, coronary artery bypass grafting.</p>
            <p id="4_00B4aiii">(iii) If you have started  new drug therapy and your response to this treatment has not yet been established; for example, beta-blocker therapy for dilated congestive  cardiomyopathy.</p>
            <p id="4_00B4b">b. In these situations, we  will obtain more evidence 3 months following the event before we evaluate your impairment. However, we will not wait if we have enough information to make a  determination or decision based on all of the relevant evidence in your case.</p>
            <p id="4_00B5">5. <em>Will we purchase any  studies?</em> 
                In appropriate situations, we will purchase studies necessary to substantiate the diagnosis or to document the severity of your impairment, 
                generally after we have evaluated the medical and other evidence we already have. 
                We will not purchase studies involving exercise testing if there is significant risk involved or if there is another medical reason not to perform the test. 
                We will follow sections <a href="#4_00C6" title="Section 4.00 - Subsection C6">4.00C6</a>, <a href="#4_00C7" title="Section 4.00 - Subsection C7">4.00C7</a>, and <a href="#4_00C8" title="Section 4.00 - Subsection C8">4.00C8</a> when we decide whether to purchase exercise testing.</p>
            <p id="4_00B6">6. <em>What studies will we not purchase?</em> 
                We will not purchase any studies involving cardiac  catheterization, such as coronary angiography, arteriograms, or electrophysiological studies. 
                However, if the results of catheterization are part of the existing evidence we have, we will consider them together with the  other relevant evidence. See <a href="#4_00C15a" title="Section 4.00 - Subsection C15a">4.00C15a.</a></p>
            <p id="4_00C"><strong>C.</strong> <em>Using Cardiovascular  Test Results</em></p>
            <p id="4_00C1">1. <em>What is an ECG?</em> </p>
            
            <p id="4_00C1a">a. <em>ECG</em> stands for <em>electrocardiograph</em> or <em>electrocardiogram.</em> An electrocardiograph is a machine that records  electrical impulses of your heart on a strip of paper called an electrocardiogram  or a <em>tracing.</em> To record the ECG, a technician positions a number of  small contacts (or <em>leads</em>) on your arms, legs, and across your chest to  connect them to the ECG machine. An ECG may be done while you are resting or  exercising.</p>
            
            <p id="4_00C1b">b. The ECG tracing may  indicate that you have a heart abnormality. It may indicate that your heart  muscle is not getting as much oxygen as it needs (ischemia), that your heart  rhythm is abnormal (arrhythmia), or that there are other abnormalities of your  heart, such as left ventricular enlargement.</p>
            
            <p id="4_00C2">2. <em>How do we evaluate  ECG evidence?</em> We consider a number of factors when we evaluate ECG  evidence:</p>
            
            <p id="4_00C2a">a. An original or legible  copy of the 12-lead ECG obtained at rest must be appropriately dated and  labeled, with the standardization inscribed on the tracing. Alteration in  standardization of specific leads (such as to accommodate large QRS amplitudes)  must be identified on those leads.</p>
            
            <p id="4_00C2ai">(i) Detailed descriptions or computer-averaged signals without original or legible copies of the ECG as described in listing <a href="#4_00C2a" title="Section 4.00 - Subsection C2a">4.00C2a</a> are not acceptable.</p>
            
            <p id="4_00C2aii">(ii) The effects of drugs or  electrolyte abnormalities must be considered as possible noncardiac causes of  ECG abnormalities of ventricular repolarization; that is, those involving the  ST segment and T wave. If available, the predrug (especially digitalis  glycosides) ECG should be submitted.</p>
            
            <p id="4_00C2b">b. ECGs obtained in  conjunction with treadmill, bicycle, or arm exercise tests should meet the  following specifications:</p>
            
            <p id="4_00C2bi">(i) ECG reports must include  the original calibrated ECG tracings or a legible copy.</p>
            
            <p id="4_00C2bii">(ii) A 12-lead baseline ECG  must be recorded in the upright position before exercise.</p>
            
            <p id="4_00C2biii">iii) A 12-lead ECG should  be recorded at the end of each minute of exercise.</p>
            
            <p id="4_00C2biv">(iv) If ECG documentation of  the effects of hyperventilation is obtained, the exercise test should be  deferred for at least 10 minutes because metabolic changes of hyperventilation  may alter the physiologic and ECG-recorded response to exercise.</p>
            
            <p id="4_00C2bv">(v) Post-exercise ECGs  should be recorded using a generally accepted protocol consistent with the  prevailing state of medical knowledge and clinical practice.</p>
            
            <p id="4_00C2bvi">(vi) All resting, exercise,  and recovery ECG strips must have the standardization inscribed on the tracing.  The ECG strips should be labeled to indicate the date, the times recorded and  the relationship to the stage of the exercise protocol. The speed and grade  (treadmill test) or work rate (bicycle or arm ergometric test) should be  recorded. The highest level of exercise achieved, heart rate and blood pressure  levels during testing, and the reason(s) for terminating the test (including  limiting signs or symptoms) must be recorded.</p>
            
            <p id="4_00C3">3. <em>What are exercise tests and what are they used for?</em> </p>
            
            <p id="4_00C3a">a. Exercise tests have you perform physical activity and record how your cardiovascular system responds.  Exercise tests usually involve walking on a treadmill, but other forms of  exercise, such as an exercise bicycle or an arm exercise machine, may be used.  Exercise testing may be done for various reasons; such as to evaluate the  severity of your coronary artery disease or peripheral vascular disease or to  evaluate your progress after a cardiac procedure or an acute event, like a  myocardial infarction (heart attack). Exercise testing is the most widely used  testing for identifying the presence of myocardial ischemia and for estimating  maximal aerobic capacity (usually expressed in METs—metabolic equivalents) if  you have heart disease.</p>
            
            <p id="4_00C3b">b. We include exercise tolerance test (ETT) criteria in <a href="#4_02B3" title="Section 4.02 - Subsection B3">4.02B3</a> (chronic heart failure) and <a href="#4_04A" title="Section 4.04 - Subsection A">4.04A</a> (ischemic heart disease).
    To meet the ETT criteria in these listings, the ETT must be a sign-or symptom-limited test in which you exercise while connected to an ECG until you develop a sign or symptom that indicates that you have
    exercised as much as is considered safe for you.
</p>
            
            <p id="4_00C3c">c. In <a href="#4_12B" title="Section 4.12 - Subsection B">4.12B</a>, we also refer to exercise testing for peripheral vascular disease. 
                In this test, you walk on a treadmill, usually for a specified period of time, and the individual who administers the test measures the effect of exercise on the flow of blood in your legs, usually by using ultrasound. 
                The test is also called an exercise Doppler test. Even though this test is intended to evaluate peripheral vascular disease, 
                it will be stopped for your safety if you develop abnormal signs or symptoms because of heart disease.</p>
            
            <p id="4_00C3d">d. Each type of test is done in a certain way following specific criteria, called a <em>protocol.</em> 
                For our program, we also specify certain aspects of how any exercise test we  purchase is to be done. See <a href="#4_00C10" title="Section 4.00 - Subsection C10">4.00C10</a> and <a href="#4_00C17" title="Section 4.00 - Subsection C17">4.00C17</a>.</p>
            
            <p id="4_00C4">4. <em>Do ETTs have  limitations?</em> An ETT provides an estimate of aerobic capacity for walking  on a grade, bicycling, or moving one's arms in an environmentally controlled  setting. Therefore, ETT results do not correlate with the ability to perform  other types of exertional activities, such as lifting and carrying heavy loads,  and do not provide an estimate of the ability to perform activities required  for work in all possible work environments or throughout a workday. Also,  certain medications (such as beta blockers) and conduction disorders (such as  left or right bundle branch blocks) can cause false-negative or false-positive  results. Therefore, we must consider the results of an ETT together with all  the other relevant evidence in your case record.</p>
            
            <p id="4_00C5">5. <em>How does an ETT with  measurement of maximal or peak oxygen uptake (VO</em>2<em>) differ  from other ETTs?</em> Occasionally, medical evidence will include the results  of an ETT with VO2. While ETTs without measurement of VO2  provide only an estimate of aerobic capacity, measured maximal or peak oxygen  uptake provides an accurate measurement of aerobic capacity, which is often  expressed in METs (metabolic equivalents). The MET level may not be indicated  in the report of attained maximal or peak VO2 testing, but can be  calculated as follows: 1 MET = 3.5 milliliters (ml) of oxygen uptake per  kilogram (kg) of body weight per minute. For example, a 70 kg (154 lb.)  individual who achieves a maximal or peak VO2 of 1225 ml in 1 minute  has attained 5 METs (1225 ml/70 kg/1 min = 17.5 ml/kg/min. 17.5/3.5 = 5 METs).</p>
            
            <p id="4_00C6">6. <em>When will we consider  whether to purchase an exercise test?</em> </p>
            
            <p id="4_00C6a">a. We will consider whether  to purchase an exercise test when:</p>
            
            <p id="4_00C6ai">(i) There is a question whether your cardiovascular impairment meets or medically equals the severity of one of the listings, 
                or there is no timely test in the evidence we have (see <a href="#4_00C9" title="Section 4.00 - Subsection C9">4.00C9</a>), and we cannot find you disabled on some other basis; or</p>
            
            <p id="4_00C6aii">(ii) We need to assess your  residual functional capacity and there is insufficient evidence in the record  to make a determination or decision.</p>
            <p id="4_00C6b">b. We will not purchase an  exercise test when we can make our determination or decision based on the  evidence we already have.</p>
            <p id="4_00C7">7. <em>What must we do  before purchasing an exercise test?</em></p>
            <p id="4_00C7a">a. Before we purchase an exercise test, an MC, preferably one with experience in the care of patients with cardiovascular disease, 
                must review the pertinent history, physical  examinations, and laboratory tests that we have to determine whether the test would present a significant risk to you or if there is some other medical 
                reason not to purchase the test (see <a href="#4_00C8" title="Section 4.00 - Subsection C8">4.00C8</a>).</p>
            <p id="4_00C7b">b. If you are under the care  of a treating source 
                (see §§ <a href="https://www.ssa.gov/OP_Home/cfr20/404/404-1502.htm" target="_blank" title="Code of Federal Regulations section 404.1502">404.1502</a> 
                and <a href="https://www.ssa.gov/OP_Home/cfr20/416/416-0902.htm" target="_blank" title="Code of Federal Regulations section 416.902">416.902</a>) for a cardiovascular impairment, 
                this source has not performed an exercise test, and there are no reported significant risks to testing, 
                we will request a statement from that source explaining why it was not done or should not be done before we decide whether we will purchase the test.</p>
            <p id="4_00C7c">c. The MC, in accordance  with the regulations and other instructions on consultative examinations, will  generally give great weight to the treating source's opinion about the risk of  exercise testing to you and will generally not override it. In the rare  situation in which the MC does override the treating source's opinion, the MC  must prepare a written rationale documenting the reasons for overriding the  opinion. </p>
            <p id="4_00C7d">d. If you do not have a  treating source or we cannot obtain a statement from your treating source, the  MC is responsible for assessing the risk to exercise testing based on a review  of the records we have before purchasing an exercise test for you.</p>
            <p id="4_00C7e">e. We must also provide your  records to the medical source who performs the exercise test for review prior  to conducting the test if the source does not already have them. The medical  source who performs the exercise test has the ultimate responsibility for  deciding whether you would be at risk.</p>
            <p id="4_00C8">8. <em>When will we not  purchase an exercise test or wait before we purchase an exercise test?</em></p>
            <p id="4_00C8a">a. We will not purchase an  exercise test when an MC finds that you have one of the following significant  risk factors:</p>
            <p id="4_00C8ai">(i) Unstable angina not  previously stabilized by medical treatment.</p>
            <p id="4_00C8aii">(ii) Uncontrolled cardiac  arrhythmias causing symptoms or hemodynamic compromise.</p>
            <p id="4_00C8aiii">(iii) An implanted cardiac  defibrillator.</p>
            <p id="4_00C8aiv">(iv) Symptomatic severe  aortic stenosis.</p>
            <p id="4_00C8av">(v) Uncontrolled symptomatic  heart failure.</p>
            <p id="4_00C8avi">(vi) Aortic dissection.</p>
            <p id="4_00C8avii">(vii) Severe pulmonary  hypertension (pulmonary artery systolic pressure greater than 60 mm Hg).</p>
            <p id="4_00C8aviii">(viii) Left main coronary  stenosis of 50 percent or greater that has not been bypassed.</p>
            <p id="4_00C8aix">(ix) Moderate stenotic  valvular disease with a systolic gradient across the aortic valve of 50 mm Hg  or greater.</p>
            <p id="4_00C8ax">(x) Severe arterial  hypertension (systolic greater than 200 mm Hg or diastolic greater than 110 mm  Hg).</p>
            <p id="4_00C8axi">(xi) Hypertrophic  cardiomyopathy with a systolic gradient of 50 mm Hg or greater.</p>
            <p id="4_00C8b">b. We also will not purchase  an exercise test when you are prevented from performing exercise testing due to  another impairment affecting your ability to use your arms and legs.</p>
            <p id="4_00C8c">c. We will not purchase an  ETT to document the presence of a cardiac arrhythmia.</p>
            <p id="4_00C8d">d. We will wait to purchase  an exercise test until 3 months after you have had one of the following events.  This will allow for maximal, attainable restoration of functional capacity.</p>
            <p id="4_00C8di">(i) Acute myocardial  infarction.</p>
            <p id="4_00C8dii">(ii) Surgical myocardial  revascularization (bypass surgery).</p>
            <p id="4_00C8diii">(iii) Other open-heart  surgical procedures.</p>
            <p id="4_00C8div">(iv) Percutaneous  transluminal coronary angioplasty with or without stenting.</p>
            <p id="4_00C8e">e. If you are deconditioned  after an extended period of bedrest or inactivity and could improve with  activity, or if you are in acute heart failure and are expected to improve with  treatment, we will wait an appropriate period of time for you to recuperate  before we purchase an exercise test.</p>
            <p id="4_00C9">9. <em>What do we mean by a  “timely” test?</em></p>
            <p id="4_00C9a">a. We consider exercise test  results to be timely for 12 months after the date they are performed, provided  there has been no change in your clinical status that may alter the severity of  your cardiovascular impairment.</p>
            <p id="4_00C9b">b. However, an exercise test  that is older than 12 months, especially an abnormal one, can still provide  information important to our adjudication. For example, a test that is more  than 12 months old can provide evidence of ischemic heart disease or peripheral  vascular disease, information on decreased aerobic capacity, or information  about the duration or onset of your impairment. Such tests can be an important  component of the longitudinal record.</p>
            <p id="4_00C9c">c. When we evaluate a test  that is more than 12 months old, we must consider the results in the context of  all the relevant evidence, including why the test was performed and whether  there has been an intervening event or improvement or worsening of your  impairment.</p>
            <p id="4_00C9d">d. We will purchase a new  exercise test only if we cannot make a determination or decision based on the  evidence we have.</p>
            <p id="4_00C10">10. <em>How must ETTs we  purchase be performed?</em></p>
            <p id="4_00C10a">a. The ETT must be a sign- or symptom-limited test characterized by a progressive multistage regimen. 
                It must be performed using a generally accepted protocol consistent with the prevailing state of medical knowledge and clinical practice. 
                A description of  the protocol that was followed must be provided, and the test must meet the requirements of <a href="#4_00C2b" title="Section 4.00 - Subsection C2b">4.00C2b</a> and this section.
    A radionuclide perfusion scan may be  useful for detecting or confirming ischemia when resting ECG abnormalities, medications, or other factors may decrease the accuracy of ECG interpretation of ischemia.
    (The perfusion imaging is done at the termination of exercise, which may be at a higher MET level than that at which ischemia first occurs.
    If the imaging confirms the presence of reversible ischemia, the exercise ECG may be useful for detecting the MET level at which ischemia initially appeared.)
    Exercise tests may also be performed using echocardiography to detect stress-induced ischemia and left ventricular dysfunction (see <a href="#4_00C12" title="Section 4.00 - Subsection C12">4.00C12</a> and <a href="#4_00C13" title="Section 4.00 - Subsection C13">4.00C13</a>).
</p>
            <p id="4_00C10b">b. The exercise test must be  paced to your capabilities and be performed following the generally accepted  standards for adult exercise test laboratories. With a treadmill test, the  speed, grade (incline), and duration of exercise must be recorded for each  exercise test stage performed. Other exercise test protocols or techniques  should use similar workloads. The exercise protocol may need to be modified in  individual cases to allow for a lower initial workload with more slowly graded  increments than the standard Bruce protocol. </p>
            <p id="4_00C10c">c. Levels of exercise must  be described in terms of workload and duration of each stage; for example,  treadmill speed and grade, or bicycle ergometer work rate in kpm/min or watts.</p>
            <p id="4_00C10d">d. The exercise laboratory's  physical environment, staffing, and equipment must meet the generally accepted  standards for adult exercise test laboratories.</p>
            <p id="4_00C11">11. <em>How do we evaluate  ETT results?</em> We evaluate ETT results on the basis of the work level at  which the test becomes abnormal, as documented by onset of signs or symptoms  and any ECG or imaging abnormalities. The absence of an ischemic response on an  ETT alone does not exclude the diagnosis of ischemic heart disease. We must  consider the results of an ETT in the context of all of the other evidence in  your case record.</p>
            <p id="4_00C12">12. <em>When are ETTs done with  imaging?</em> When resting ECG abnormalities preclude interpretation of ETT  tracings relative to ischemia, a radionuclide (for example, thallium-201 or  technetium-99m) perfusion scan or echocardiography in conjunction with an ETT  provides better results. You may have resting ECG abnormalities when you have a  conduction defect—for example, Wolff-Parkinson-White syndrome, left bundle  branch block, left ventricular hypertrophy—or when you are taking digitalis or  other antiarrhythmic drugs, or when resting ST changes are present. Also, these  techniques can provide a reliable estimate of ejection fraction.</p>
            <p id="4_00C13">13. <em>Will we purchase ETTs with imaging?</em> 
                We may purchase an ETT with imaging in your case after an MC, preferably one with experience in the care of patients with cardiovascular disease, 
                has reviewed your medical history and physical examination, any report(s) of appropriate medically acceptable imaging, ECGs, and other appropriate tests. 
                We will consider purchasing an ETT with imaging when other information we have is not adequate for us to assess whether you have severe ventricular dysfunction or myocardial ischemia, 
                there is no significant risk involved (see <a href="#4_00C8a" title="Section 4.00 - Subsection C8a">4.00C8a</a>), and we cannot make our determination or decision based on the evidence we already have.</p>
            <p id="4_00C14">14. <em>What are drug-induced stress tests?</em> These tests are designed primarily to provide  evidence about myocardial ischemia or prior myocardial infarction, but do not  require you to exercise. These tests are used when you cannot exercise or  cannot exercise enough to achieve the desired cardiac stress. Drug-induced  stress tests can also provide evidence about heart chamber dimensions and  function; however, these tests do not provide information about your aerobic  capacity and cannot be used to help us assess your ability to function. Some of  these tests use agents, such as Persantine or adenosine, that dilate the  coronary arteries and are used in combination with nuclear agents, such as  thallium or technetium (for example, Cardiolyte or Myoview), and a myocardial scan.  Other tests use agents, such as dobutamine, that stimulate the heart to  contract more forcefully and faster to simulate exercise and are used in  combination with a 2-dimensional echocardiogram. We may, when appropriate,  purchase a drug-induced stress test to confirm the presence of myocardial  ischemia after a review of the evidence in your file by an MC, preferably one  with experience in the care of patients with cardiovascular disease.</p>
            <p id="4_00C15">15. <em>How do we evaluate  cardiac catheterization evidence?</em></p>
            <p id="4_00C15a">a. We will not purchase  cardiac catheterization; however, if you have had catheterization, we will make  every reasonable effort to obtain the report and any ancillary studies. We will  consider the quality and type of data provided and its relevance to the evaluation  of your impairment. For adults, we generally see two types of catheterization  reports: Coronary arteriography and left ventriculography.</p>
            <p id="4_00C15b">b. For coronary  arteriography, the report should provide information citing the method of  assessing coronary arterial lumen diameter and the nature and location of  obstructive lesions. Drug treatment at baseline and during the procedure should  be reported. Some individuals with significant coronary atherosclerotic  obstruction have collateral vessels that supply the myocardium distal to the  arterial obstruction so that there is no evidence of myocardial damage or  ischemia, even with exercise. When the results of quantitative computer  measurements and analyses are included in your case record, we will consider  them in interpreting the severity of stenotic lesions.</p>
            <p id="4_00C15c">c. For left  ventriculography, the report should describe the wall motion of the myocardium  with regard to any areas of hypokinesis (abnormally decreased motion), akinesis  (lack of motion), or dyskinesis (distortion of motion), and the overall  contraction of the ventricle as measured by the ejection fraction. Measurement  of chamber volumes and pressures may be useful. Quantitative computer analysis  provides precise measurement of segmental left ventricular wall thickness and  motion. There is often a poor correlation between left ventricular function at  rest and functional capacity for physical activity.</p>
            <p id="4_00C16">16. <em>What details should  exercise Doppler test reports contain?</em> The reports of exercise Doppler  tests must describe the level of exercise; for example, the speed and grade of  the treadmill settings, the duration of exercise, symptoms during exercise, and  the reasons for stopping exercise if the expected level of exercise was not  attained. They must also include the blood pressures at the ankle and other  pertinent sites measured after exercise and the time required for the systolic  blood pressure to return toward or to the pre-exercise level. The graphic  tracings, if available, should also be included with the report. All tracings  must be annotated with the standardization used by the testing facility.</p>
            <p id="4_00C17">17. <em>How must exercise Doppler tests we purchase be performed?</em> 
                When we purchase an exercise Doppler test, you must exercise on a treadmill at 2 mph on a 12 percent grade for up to 5 minutes. 
                The reports must include the information specified in <a href="#4_00C16" title="Section 4.00 - Subsection C16">4.00C16</a>.
    Because this is an exercise test, we must evaluate whether such testing would put you at significant risk,
    in accordance with the guidance found in <a href="#4_00C6" title="Section 4.00 - Subsection C6">4.00C6</a>, <a href="#4_00C7" title="Section 4.00 - Subsection C7">4.00C7</a>, and <a href="#4_00C8" title="Section 4.00 - Subsection C8">4.00C8</a>.
</p>
            <p id="4_00D"><strong>D.</strong> <em>Evaluating  Chronic Heart Failure </em></p>
            <p id="4_00D1">1. <em>What is chronic heart  failure (CHF)?</em></p>
            <p id="4_00D1a">a. <em>CHF</em> is the  inability of the heart to pump enough oxygenated blood to body tissues. This  syndrome is characterized by symptoms and signs of pulmonary or systemic  congestion (fluid retention) or limited cardiac output. Certain laboratory  findings of cardiac functional and structural abnormality support the diagnosis  of CHF. There are two main types of CHF:</p>
            <p id="4_00D1ai">(i) <em>Predominant systolic  dysfunction</em> (the inability of the heart to contract normally and expel  sufficient blood), which is characterized by a dilated, poorly contracting left  ventricle and reduced ejection fraction (abbreviated EF, it represents the  percentage of the blood in the ventricle actually pumped out with each contraction),  and</p>
            <p id="4_00D1aii">(ii) <em>Predominant  diastolic dysfunction</em> (the inability of the heart to relax and fill  normally), which is characterized by a thickened ventricular muscle, poor  ability of the left ventricle to distend, increased ventricular filling pressure,  and a normal or increased EF.</p>
            <p id="4_00D1b">b. CHF is considered in  these listings as a single category whether due to atherosclerosis (narrowing  of the arteries), 
                cardiomyopathy, hypertension, or rheumatic, congenital, or  other heart disease. 
                However, if the CHF is the result of primary pulmonary hypertension secondary to disease of the lung (cor pulmonale), 
                we will evaluate your impairment using <a href="3.00-Respiratory-Adult.htm#3_09" title="3.00 Respiratory Disorders Page, Section 3.09" target="_blank">3.09</a>, in the respiratory system listings.</p>
            <p id="4_00D2">2. <em>What evidence of CHF  do we need?</em></p>
            <p id="4_00D2a">a. Cardiomegaly or ventricular dysfunction must be present and demonstrated by appropriate  medically acceptable imaging, such as chest x-ray, echocardiography (M-Mode,  2-dimensional, and Doppler), radionuclide studies, or cardiac catheterization.</p>
            <p id="4_00D2ai">(i) Abnormal cardiac imaging showing increased left ventricular end diastolic diameter (LVEDD), decreased  EF, increased left atrial chamber size, increased ventricular filling pressures  measured at cardiac catheterization, or increased left ventricular wall or  septum thickness, provides objective measures of both left ventricular function  and structural abnormality in heart failure.</p>
            <p id="4_00D2aii">(ii) An LVEDD greater than 6.0 cm or an EF of 30 percent or less measured during a period of stability  (that is, not during an episode of acute heart failure) may be associated  clinically with systolic failure.</p>
            <p id="4_00D2aiii">(iii) Left ventricular posterior wall thickness added to septal thickness totaling 2.5 cm or greater  with left atrium enlarged to 4.5 cm or greater may be associated clinically  with diastolic failure.</p>
            <p id="4_00D2aiv">(iv) However, these measurements alone do not reflect your functional capacity, which we evaluate  by considering all of the relevant evidence. In some situations, we may need to  purchase an ETT to help us assess your functional capacity.</p>
            <p id="4_00D2av">(v) Other findings on appropriate medically acceptable imaging may include increased pulmonary  vascular markings, pleural effusion, and pulmonary edema. These findings need  not be present on each report, since CHF may be controlled by prescribed  treatment.</p>
            <p id="4_00D2b">b. To establish that you have <em>chronic</em> heart failure, your medical history and physical  examination should describe characteristic symptoms and signs of pulmonary or  systemic congestion or of limited cardiac output associated with the abnormal  findings on appropriate medically acceptable imaging. When an acute episode of  heart failure is triggered by a remediable factor, such as an arrhythmia,  dietary sodium overload, or high altitude, cardiac function may be restored and  a chronic impairment may not be present.</p>
            <p id="4_00D2bi">(i) Symptoms of congestion  or of limited cardiac output include easy fatigue, weakness, shortness of  breath (dyspnea), cough, or chest discomfort at rest or with activity.  Individuals with CHF may also experience shortness of breath on lying flat  (orthopnea) or episodes of shortness of breath that wake them from sleep  (paroxysmal nocturnal dyspnea). They may also experience cardiac arrhythmias  resulting in palpitations, lightheadedness, or fainting.</p>
            <p id="4_00D2bii">(ii) Signs of congestion may include hepatomegaly, ascites, increased jugular venous distention or pressure,  rales, peripheral edema, or rapid weight gain. However, these signs need not be  found on all examinations because fluid retention may be controlled by  prescribed treatment.</p>
            <p id="4_00D3">3. <em>Is it safe for you to  have an ETT, if you have CHF?</em>
                The presence of CHF is not necessarily a contraindication to an ETT, unless you are having an acute episode of heart failure.
                Measures of cardiac performance are valuable in helping us evaluate  your ability to do work-related activities.
                Exercise testing has been safely  used in individuals with CHF; therefore, we may purchase an ETT for evaluation under <a href="#4_02B3" title="Section 4.02 - Subsection B3">4.02B3</a> if an MC,
                preferably one experienced in the care of patients with cardiovascular disease, determines that there is no significant risk to you.
                (See  <a href="#4_00C6" title="Section 4.00 - Subsection C6">4.00C6</a> for when we will consider the purchase of an ETT. See <a href="#4_00C7" title="Section 4.00 - Subsection C7">4.00C7</a>- <a href="#4_00C8" title="Section 4.00 - Subsection C8">4.00C8</a> for what we must do before we purchase an ETT and when we will not purchase one.)
        ST segment changes from digitalis use in the treatment of CHF do not preclude  the purchase of an ETT.
</p>
            <p id="4_00D4">4. <em>How do we evaluate CHF using  <a href="#4_02" title="Section 4.02">4.02</a>?</em></p>
            <p id="4_00D4a">a. We must have objective  evidence, as described in  <a href="#4_00D2" title="Section 4.00 - Subsection D2">4.00D2</a>, that you have chronic heart failure.</p>
            <p id="4_00D4b">b. To meet the required  level of severity for this listing, your impairment must satisfy the  requirements of one of the criteria in A and one of the criteria in B.</p>
            <p id="4_00D4c">c. In <a href="#4_02B2" title="Section 4.02 - Subsection B2">4.02B2</a>, the phrase <em>periods of stabilization</em> means that, for at least 2 weeks between episodes of  acute heart failure, there must be objective evidence of clearing of the  pulmonary edema or pleural effusions and evidence that you returned to, or you  were medically considered able to return to, your prior level of activity.</p>
            <p id="4_00D4d">d. Listing  <a href="#4_02B3c" title="Section 4.02 - Subsection B3c">4.02B3c</a> requires  a decrease in systolic blood pressure below the baseline level (taken in the  standing position immediately prior to exercise) or below any systolic pressure  reading recorded during exercise. This is because, normally, systolic blood  pressure and heart rate increase gradually with exercise. Decreases in systolic  blood pressure below the baseline level that occur during exercise are often  associated with ischemia-induced left ventricular dysfunction resulting in  decreased cardiac output. However, a blunted response (that is, failure of the  systolic blood pressure to rise 10 mm Hg or more), particularly in the first 3  minutes of exercise, may be drug-related and is not necessarily associated with  left ventricular dysfunction. Also, some individuals with increased sympathetic  responses because of deconditioning or apprehension may increase their systolic  blood pressure and heart rate above their baseline level just before and early  into exercise. This can be associated with a drop in systolic pressure in early  exercise that is not due to left ventricular dysfunction. Therefore, an early  decrease in systolic blood pressure must be interpreted within the total  context of the test; that is, the presence or absence of symptoms such as  lightheadedness, ischemic changes, or arrhythmias on the ECG.</p>
            <p id="4_00E"><strong>E.</strong> <em>Evaluating  Ischemic Heart Disease </em></p>
            <p id="4_00E1">1. <em>What is ischemic  heart disease (IHD)? IHD</em> results when one or more of your coronary  arteries is narrowed or obstructed or, in rare situations, constricted due to  vasospasm, interfering with the normal flow of blood to your heart muscle  (ischemia). The obstruction may be the result of an embolus, a thrombus, or  plaque. When heart muscle tissue dies as a result of the reduced blood supply,  it is called a myocardial infarction (heart attack).</p>
            <p id="4_00E2">2. <em>What causes chest  discomfort of myocardial origin?</em></p>
            <p id="4_00E2a">a. Chest discomfort of  myocardial ischemic origin, commonly known as angina pectoris, is usually  caused by coronary artery disease (often abbreviated CAD). However, ischemic  discomfort may be caused by a noncoronary artery impairment, such as aortic  stenosis, hypertrophic cardiomyopathy, pulmonary hypertension, or anemia.</p>
            <p id="4_00E2b">b. Instead of typical angina  pectoris, some individuals with IHD experience atypical angina, anginal  equivalent, variant angina, or silent ischemia,
                all of which we may evaluate using  <a href="#4_04" title="Section 4.04">4.04</a>.
                We discuss the various manifestations of ischemia in  <a href="#4_00E3" title="Section 4.00 - Subsection E3">4.00E3</a>-<a href="#4_00E7" title="Section 4.00 - Subsection E7">4.00E7</a>.
            </p>
            <p id="4_00E3">3. <em>What are the  characteristics of typical angina pectoris?</em> Discomfort of myocardial  ischemic origin (angina pectoris) is discomfort that is precipitated by effort  or emotion and promptly relieved by rest, sublingual nitroglycerin (that is,  nitroglycerin tablets that are placed under the tongue), or other rapidly  acting nitrates. Typically, the discomfort is located in the chest (usually  substernal) and described as pressing, crushing, squeezing, burning, aching, or  oppressive. Sharp, sticking, or cramping discomfort is less common. Discomfort  occurring with activity or emotion should be described specifically as to  timing and usual inciting factors (type and intensity), character, location,  radiation, duration, and response to nitrate treatment or rest.</p>
            <p id="4_00E4">4. <em>What is atypical  angina? Atypical angina</em> describes discomfort or pain from myocardial  ischemia that is felt in places other than the chest. The common sites of  cardiac pain are the inner aspect of the left arm, neck, jaw(s), upper abdomen,  and back, but the discomfort or pain can be elsewhere. When pain of cardiac  ischemic origin presents in an atypical site in the absence of chest  discomfort, the source of the pain may be difficult to diagnose. To represent  atypical angina, your discomfort or pain should have precipitating and  relieving factors similar to those of typical chest discomfort, and we must  have objective medical evidence of myocardial ischemia; for example, ECG or ETT  evidence or appropriate medically acceptable imaging.</p>
            <p id="4_00E5">5. <em>What is anginal equivalent?</em> Often, individuals with IHD will complain of shortness of  breath (dyspnea) on exertion without chest pain or discomfort. In a minority of  such situations, the shortness of breath is due to myocardial ischemia; this is  called <em>anginal equivalent</em>. To represent anginal equivalent, your  shortness of breath should have precipitating and relieving factors similar to  those of typical chest discomfort, and we must have objective medical evidence  of myocardial ischemia; for example, ECG or ETT evidence or appropriate  medically acceptable imaging. In these situations, it is essential to establish  objective evidence of myocardial ischemia to ensure that you do not have effort  dyspnea due to non-ischemic or non-cardiac causes.</p>
            <p id="4_00E6">6. <em>What is variant angina?</em></p>
            <p id="4_00E6a">a. <em>Variant angina</em> (Prinzmetal's angina, vasospastic angina) refers to the occurrence of anginal episodes at rest, especially at night,
                accompanied by transitory ST segment elevation (or, at times, ST depression) on an ECG.
                It is due to severe spasm of  a coronary artery, causing ischemia of the heart wall, and is often accompanied by major ventricular arrhythmias, such as ventricular tachycardia.
                We will consider variant angina under  <a href="#4_04" title="Section 4.04">4.04</a> only if you have spasm of a coronary artery in relation to an obstructive lesion of the vessel.
                If you have an arrhythmia as a result of variant angina, we may consider your impairment under  <a href="#4_05" title="Section 4.05">4.05</a>.
            </p>
            <p id="4_00E6b">b. Variant angina may also  occur in the absence of obstructive coronary disease. In this situation, an ETT  will not demonstrate ischemia. The diagnosis will be established by showing the  typical transitory ST segment changes during attacks of pain, and the absence  of obstructive lesions shown by catheterization. Treatment in cases where there  is no obstructive coronary disease is limited to medications that reduce  coronary vasospasm, such as calcium channel blockers and nitrates. In such  situations, we will consider the frequency of anginal episodes despite  prescribed treatment when evaluating your residual functional capacity.</p>
            <p id="4_00E6c">c. Vasospasm that is  catheter-induced during coronary angiography is not variant angina.</p>
            <p id="4_00E7">7. <em>What is silent  ischemia?</em></p>
            <p id="4_00E7a">a. Myocardial ischemia, and  even myocardial infarction, can occur without perception of pain or any other  symptoms; when this happens, we call it <em>silent ischemia</em>. Pain  sensitivity may be altered by a variety of diseases, most notably diabetes  mellitus and other neuropathic disorders. Individuals also vary in their  threshold for pain.</p>
            <p id="4_00E7b">b. Silent ischemia occurs  most often in:</p>
            <p id="4_00E7bi">(i) Individuals with  documented past myocardial infarction or established angina without prior  infarction who do not have chest pain on ETT, but have a positive test with  ischemic abnormality on ECG, perfusion scan, or other appropriate medically  acceptable imaging.</p>
            <p id="4_00E7bii">(ii) Individuals with  documented past myocardial infarction or angina who have ST segment changes on  ambulatory monitoring (Holter monitoring) that are similar to those that occur  during episodes of angina. ST depression shown on the ambulatory recording  should not be interpreted as positive for ischemia unless similar depression is  also seen during chest pain episodes annotated in the diary that the individual  keeps while wearing the Holter monitor.</p>
            <p id="4_00E7c">c. ST depression can result from a variety of factors, such as postural changes and variations in cardiac sympathetic tone.
                In addition, there are differences in how different Holter monitors record the electrical responses.
                Therefore, we do not consider the  Holter monitor reliable for the diagnosis of silent ischemia except in the  situation described in  <a href="#4_00E7bii" title="Section 4.00 - Subsection E7b(ii)">4.00E7b(ii)</a>.
            </p>
            <p id="4_00E8">8. <em>What other sources of  chest discomfort are there?</em> Chest discomfort of nonischemic origin may  result from other cardiac impairments, such as pericarditis. Noncardiac impairments  may also produce symptoms mimicking that of myocardial ischemia. These  impairments include acute anxiety or panic attacks, gastrointestinal tract  disorders, such as esophageal spasm, esophagitis, hiatal hernia, biliary tract  disease, gastritis, peptic ulcer, and pancreatitis, and musculoskeletal  syndromes, such as chest wall muscle spasm, chest wall syndrome (especially  after coronary bypass surgery), costochondritis, and cervical or dorsal spine  arthritis. Hyperventilation may also mimic ischemic discomfort. Thus, in the  absence of documented myocardial ischemia, such disorders should be considered  as possible causes of chest discomfort.</p>
            <p id="4_00E9">9. <em>How do we evaluate IHD using  <a href="#4_04" title="Section 4.04">4.04</a>?</em></p>
            <p id="4_00E9a">a. We must have objective evidence, as described under  <a href="#4_00C" title="Section 4.00 - Subsection C">4.00C</a>, that your symptoms are due to myocardial ischemia.</p>
            <p id="4_00E9b">b. Listing-level changes on  the ECG in <a href="#4_04A1" title="Section 4.04 - Subsection A1">4.04A1</a> are the classically accepted changes of horizontal or
                downsloping ST depression occurring both during exercise and recovery.
                Although we recognize that ischemic changes may at times occur only during exercise or  recovery, and may at times be upsloping with only junctional ST depression, such changes can be false positive; that is,
                occur in the absence of ischemia.  Diagnosis of ischemia in this situation requires radionuclide or echocardiogram confirmation.
                See  <a href="#4_00C12" title="Section 4.00 - Subsection C12">4.00C12</a> and  <a href="#4_00C13" title="Section 4.00 - Subsection C13">4.00C13</a>.
            </p>
            <p id="4_00E9c">c. Also in  <a href="#4_04A1" title="Section 4.04 - Subsection A1">4.04A1</a>, 
                we require that the depression of the ST segment last for at least 1 minute of recovery because ST depression that occurs during exercise but that rapidly normalizes in recovery is a common false-positive response.</p>
            <p id="4_00E9d">
               d. In  <a href="#4_04A2" title="Section 4.04 - Subsection A2">4.04A2</a>, we specify that the ST elevation must be in non-infarct leads during both exercise and recovery.
                This is because, in the absence of ECG signs of prior infarction, ST elevation during exercise denotes ischemia, usually severe, requiring immediate termination of exercise.
                However, if there is baseline ST elevation in association with a prior infarction or ventricular aneurysm,
                further ST elevation during exercise does not necessarily denote ischemia and could be a false-positive ECG response.
                Diagnosis of ischemia in this situation requires  radionuclide or echocardiogram confirmation. See <a href="#4_00C12" title="Section 4.00 - Subsection C12">4.00C12</a> and  <a href="#4_00C13" title="Section 4.00 - Subsection C13">4.00C13</a>.
            </p>
            <p id="4_00E9e">e. Listing  <a href="#4_04A3" title="Section 4.04 - Subsection A3">4.04A3</a> requires a decrease in systolic blood pressure below the baseline level
                (taken in the standing position immediately prior to exercise) or below any systolic pressure reading recorded during exercise.
                This is the same finding required in  <a href="#4_02B3c" title="Section 4.02 - Subsection B3c">4.02B3c</a>.  See  <a href="#4_00D4d" title="Section 4.00 - Subsection D4d">4.00D4d</a> for full details.
            </p>
            <p id="4_00E9f">f. In  <a href="#4_04B" title="Section 4.00 - Subsection B">4.04B</a>, each of the three ischemic episodes must require revascularization or be not amenable to treatment. 
                <em>Revascularization</em> means angioplasty (with or without stent  placement) or bypass surgery. 
                However, reocclusion that occurs after a revascularization procedure but during the same hospitalization and that requires a second procedure during the same hospitalization will not be counted as another ischemic episode. Not amenable means that the revascularization  procedure could not be done because of another medical impairment or because  the vessel was not suitable for revascularization.</p>
            <p id="4_00E9g">g. We will use <a href="#4_04C" title="Section 4.04 - Subsection C">4.04C</a> only when you have symptoms due to myocardial ischemia as described in </p>
            <p><a href="#4_00E3" title="Section 4.00 - Subsection E3">4.00E3</a>-<a href="#4_00E7" title="Section 4.00 - Subsection E7">4.00E7</a> while on a regimen of prescribed treatment, 
                you are at risk for exercise testing (see <a href="#4_00C8" title="Section 4.00 - Subsection C8">4.00C8</a>), and we do not have a timely ETT or a timely normal drug-induced stress test for you. 
                See <a href="#4_00C9" title="Section 4.00 - Subsection C9">4.00C9</a> for what we mean by a timely test.</p>
            <p id="4_00E9h">h. In <a href="#4_04C1" title="Section 4.04 - Subsection C1">4.04C1</a> the term <em>nonbypassed</em> means that the blockage is in a vessel that is potentially bypassable; 
                that is, large enough to be bypassed and considered to be a cause of your ischemia.  
                These vessels are usually major arteries or one of a major artery's major  branches. 
                A vessel that has become obstructed again after angioplasty or stent placement and has remained obstructed or is not amenable to another revascularization is considered a nonbypassed vessel for purposes of this listing. 
                When you have had revascularization, we will not use the pre-operative findings to assess the current severity of your coronary artery disease under <a href="#4_04C" title="Section 4.04 - Subsection C">4.04C</a>,
    although we will consider the severity and duration of your impairment  prior to your surgery in making our determination or decision.
</p>
            <p id="4_00F"><strong>F.</strong><em> Evaluating  Arrhythmias </em></p>
            <p id="4_00F1">1. <em>What is an  arrhythmia?</em> An <em>arrhythmia</em> is a change in the regular beat of the  heart. Your heart may seem to skip a beat or beat irregularly, very quickly  (tachycardia), or very slowly (bradycardia).</p>
            <p id="4_00F2">2. <em>What are the  different types of arrhythmias?</em></p>
            <p id="4_00F2a">a. There are many types of  arrhythmias. Arrhythmias are identified by where they occur in the heart (atria  or ventricles) and by what happens to the heart's rhythm when they occur.</p>
            <p id="4_00F2b">b. Arrhythmias arising in  the cardiac atria (upper chambers of the heart) are called atrial or  supraventricular arrhythmias. Ventricular arrhythmias begin in the ventricles  (lower chambers). In general, ventricular arrhythmias caused by heart disease  are the most serious.</p>
            <p id="4_00F3">3. <em>How do we evaluate  arrhythmias using <a href="#4_05" title="Section 4.05">4.05</a>?</em></p>
            <p id="4_00F3a">a. We will use <a href="#4_05" title="Section 4.05">4.05</a> when you  have arrhythmias that are not fully controlled by medication, an implanted  pacemaker, 
                or an implanted cardiac defibrillator and you have uncontrolled  recurrent episodes of syncope or near syncope.
                If your arrhythmias are controlled, we will evaluate your underlying heart disease using the  appropriate listing. 
                For other considerations when we evaluate arrhythmias in the presence of an implanted cardiac defibrillator, see <a href="#4_00F4" title="Section 4.00 - Subsection F4">4.00F4</a>.</p>
            <p id="4_00F3b">b. We consider <em>near  syncope</em> to be a period of altered consciousness, since syncope is a loss of consciousness or a faint. It is not merely a feeling of light-headedness,  momentary weakness, or dizziness.</p>
            <p id="4_00F3c">c. For purposes of <a href="#4_05" title="Section 4.05">4.05</a>, there must be a documented association between the syncope or near syncope and  the recurrent arrhythmia. The recurrent arrhythmia, not some other cardiac or  non-cardiac disorder, must be established as the cause of the associated  symptom. This documentation of the association between the symptoms and the  arrhythmia may come from the usual diagnostic methods, including Holter  monitoring (also called ambulatory electrocardiography) and tilt-table testing  with a concurrent ECG. Although an arrhythmia may be a coincidental finding on  an ETT, we will not purchase an ETT to document the presence of a cardiac  arrhythmia.</p>
            <p id="4_00F4">4. <em>What will we consider  when you have an implanted cardiac defibrillator and you do not have  arrhythmias that meet the requirements of <a href="#4_05" title="Section 4.05">4.05</a>?</em></p>
            <p id="4_00F4a">a. Implanted cardiac  defibrillators are used to prevent sudden cardiac death in individuals who have  had, or are at high risk for, 
                cardiac arrest from life-threatening ventricular arrhythmias. The largest group at risk for sudden cardiac death consists of individuals with cardiomyopathy (ischemic or non-ischemic) and reduced ventricular function. 
                However, life-threatening ventricular arrhythmias can also occur in individuals with little or no ventricular dysfunction. 
                The shock from the implanted cardiac defibrillator is a unique form of treatment; it rescues an individual from what may have been cardiac arrest. 
                However, as a consequence of the shock(s), individuals may experience psychological distress, which we may evaluate under the mental disorders listings in <a href="12.00-MentalDisorders-Adult.htm#12_00ff" title="12.00 Neurological Disorders Page, Section 12.00 - Subsection FF" target="_blank">12.00ff</a>.</p>
            <p id="4_00F4b">b. Most implantable cardiac  defibrillators have rhythm-correcting and pacemaker capabilities. In some  individuals, these functions may result in the termination of ventricular arrhythmias  without an otherwise painful shock. (The shock is like being kicked in the  chest.) Implanted cardiac defibrillators may deliver inappropriate shocks,  often repeatedly, in response to benign arrhythmias or electrical malfunction.  Also, exposure to strong electrical or magnetic fields, such as from MRI  (magnetic resonance imaging), can trigger or reprogram an implanted cardiac  defibrillator, resulting in inappropriate shocks. We must consider the  frequency of, and the reason(s) for, the shocks when evaluating the severity  and duration of your impairment.</p>
            <p id="4_00F4c">c. In general, the exercise  limitations imposed on individuals with an implanted cardiac defibrillator are  those dictated by the underlying heart impairment. However, the exercise  limitations may be greater when the implanted cardiac defibrillator delivers an  inappropriate shock in response to the increase in heart rate with exercise, or  when there is exercise-induced ventricular arrhythmia.</p>
            <p id="4_00G"><strong>G.</strong> <em>Evaluating  Peripheral Vascular Disease </em></p>
            <p id="4_00G1">1. <em>What is peripheral  vascular disease (PVD)?</em> Generally, <em>PVD</em> is any impairment that  affects either the arteries (peripheral arterial disease) or the veins (venous  insufficiency) in the extremities, particularly the lower extremities. The  usual effect is blockage of the flow of blood either from the heart (arterial)  or back to the heart (venous). If you have peripheral arterial disease, you may  have pain in your calf after walking a distance that goes away when you rest  (intermittent claudication); at more advanced stages, you may have pain in your  calf at rest or you may develop ulceration or gangrene. If you have venous  insufficiency, you may have swelling, varicose veins, skin pigmentation  changes, or skin ulceration.</p>
            <p id="4_00G2">2. <em>How do we assess  limitations resulting from PVD?</em> 
                We will assess your limitations based on  your symptoms together with physical findings, Doppler studies, other  appropriate non-invasive studies, or angiographic findings. 
                However, if the PVD  has resulted in amputation, we will evaluate any limitations related to the  amputation under the musculoskeletal listings, 
                <a href="1.00-Musculoskeletal-Adult.htm#1_00ff" title="1.00 Musculoskeletal System Page, Section 1.00 - Subsection FF" target="_blank">1.00ff</a>.</p>
            <p id="4_00G3">3. <em>What is brawny edema? Brawny edema</em> (<a href="#4_11A" title="Section 4.11 - Subsection A">4.11A</a>) 
                is swelling that is usually dense and feels firm due to the presence of increased connective tissue; it is also associated with  characteristic skin pigmentation changes. 
                It is not the same thing as pitting edema. Brawny edema generally does not pit (indent on pressure), and the terms  are not interchangeable. 
                Pitting edema does not satisfy the requirements of <a href="#4_11A" title="Section 4.11 - Subsection A">4.11A</a>.</p>
            <p id="4_00G4">4. <em>What is lymphedema and how will we evaluate it?</em></p>
            <p id="4_00G4a">a. <em>Lymphedema</em> is edema of the extremities due to a disorder of the lymphatic circulation; at its  worst, it is called elephantiasis. Primary lymphedema is caused by abnormal  development of lymph vessels and may be present at birth (congenital  lymphedema), but more often develops during the teens (lymphedema praecox). It  may also appear later, usually after age 35 (lymphedema tarda). Secondary  lymphedema is due to obstruction or destruction of normal lymphatic channels  due to tumor, surgery, repeated infections, or parasitic infection such as  filariasis. Lymphedema most commonly affects one extremity.</p>
            <p id="4_00G4b">b. Lymphedema does not meet the requirements of <a href="#4_11" title="Section 4.11">4.11</a>, although it may medically equal the severity of that listing. 
                We will evaluate lymphedema by considering whether the underlying cause meets or medically equals any listing or whether the lymphedema medically equals a cardiovascular listing, 
                such as <a href="#4_11" title="Section 4.11">4.11</a>, or a musculoskeletal disorders listing, 
                such as <a href="1.00-Musculoskeletal-Adult.htm#1_18" title="1.00 Musculoskeletal System Page, Section 1.18" target="_blank">1.18</a> <!--<a href="1.00-Musculoskeletal-Adult.htm#1_02A" title="1.00 Musculoskeletal System Page, Section 1.02 - Subsection A" target="_blank">1.02A</a> 
                or <a href="1.00-Musculoskeletal-Adult.htm#1_03" title="1.00 Musculoskeletal System Page, Section 1.03" target="_blank">1.03</a>-->.
    If no listing is met or medically equaled, we will evaluate any functional limitations imposed by your lymphedema when we assess  your residual functional capacity.
</p>
            <p id="4_00G5">5. <em>When will we purchase exercise Doppler studies for evaluating peripheral arterial disease (PAD)?</em> 
                If we need additional evidence of your PAD, we will generally purchase exercise Doppler studies (see <a href="#4_00C16" title="Section 4.00 - Subsection C16">4.00C16</a> and <a href="#4_00C17" title="Section 4.00 - Subsection C17">4.00C17</a>)
    when your resting ankle/brachial systolic blood pressure ratio is at least 0.50 but less than 0.80, and only  rarely when it is 0.80 or above.
    We will not purchase exercise Doppler testing  if you have a disease that results in abnormal arterial calcification or small vessel disease,
    but will use your resting toe systolic blood pressure or resting toe/brachial systolic blood pressure ratio.
    (See <a href="#4_00G7c" title="Section 4.00 - Subsection G7c">4.00G7c</a> and <a href="#4_00G8" title="Section 4.00 - Subsection G8">4.00G8.</a>)  There are no current medical standards for evaluating exercise toe pressures.
    Because any exercise test stresses your entire cardiovascular system, we will purchase exercise Doppler studies only after an MC, preferably one with experience in the care of patients with cardiovascular disease,
    has determined that the test would not present a significant risk to you and that there is no  other medical reason not to purchase the test
    (see <a href="#4_00C6" title="Section 4.00 - Subsection C6">4.00C6</a>, <a href="#4_00C7" title="Section 4.00 - Subsection C7">4.00C7</a>, and <a href="#4_00C8" title="Section 4.00 - Subsection C8">4.00C8</a>).
</p>
            <p id="4_00G6">6. <em>Are there any other studies that are helpful in evaluating PAD?</em> Doppler studies done using a  recording ultrasonic Doppler unit and strain-gauge plethysmography are other  useful tools for evaluating PAD. A recording Doppler, which prints a tracing of  the arterial pulse wave in the femoral, popliteal, dorsalis pedis, and  posterior tibial arteries, is an excellent evaluation tool to compare wave  forms in normal and compromised peripheral blood flow. Qualitative analysis of  the pulse wave is very helpful in the overall assessment of the severity of the  occlusive disease. Tracings are especially helpful in assessing severity if you  have small vessel disease related to diabetes mellitus or other diseases with  similar vascular changes, or diseases causing medial calcifications when ankle  pressure is either normal or falsely high.</p>
            <p id="4_00G7">7. <em>How do we evaluate PAD under <a href="#4_12" title="Section 4.12">4.12</a>?</em></p>
            <p id="4_00G7a">a. The ankle blood pressure referred to in <a href="#4_12A" title="Section 4.12 - Subsection A">4.12A</a> and <a href="#4_12B" title="Section 4.12 - Subsection B">B</a> 
                is the higher of the pressures recorded from the  posterior tibial and dorsalis pedis arteries in the affected leg. 
                The higher pressure recorded from the two sites is the more significant measurement in assessing the extent of arterial insufficiency. 
                Techniques for obtaining ankle systolic blood pressures include Doppler (See <a href="#4_00C16" title="Section 4.00 - Subsection C16">4.00C16</a> and <a href="#4_00C16" title="Section 4.00 - Subsection C17">4.00C17</a>),
    plethysmographic studies, or other techniques. We will request any available tracings generated by these studies so that we can review them.
</p>
            <p id="4_00G7b">b. In <a href="#4_12A" title="Section 4.12 - Subsection A">4.12A</a>, the ankle/brachial systolic blood pressure ratio is the ratio of the systolic blood pressure at the 
                ankle to the systolic blood pressure at the brachial artery;  both taken at the same time while you are lying on your back. 
                We do not require that the ankle and brachial pressures be taken on the same side of your body.  This is because, as with the ankle pressure, we will use the higher brachial  systolic pressure measured. 
                Listing <a href="#4_12A" title="Section 4.12 - Subsection A">4.12A</a> is met when your resting ankle/brachial systolic blood pressure ratio is less than 0.50.
    If your resting ankle/brachial systolic blood pressure ratio is 0.50 or above, we will use 4.12B to evaluate the severity of your PAD,
    unless you also have a disease causing abnormal arterial calcification or small vessel disease, such as diabetes mellitus.
    See <a href="#4_00G7c" title="Section 4.00 - Subsection G7c">4.00G7c</a> and <a href="#4_00G8" title="Section 4.00 - Subsection G8">4.00G8</a>.
</p>
            <p id="4_00G7c">c. We will use resting toe systolic blood pressures or resting toe/brachial systolic blood pressure ratios 
                (determined the same way as ankle/brachial ratios, see <a href="#4_00G7b" title="Section 4.00 - Subsection G7b">4.00G7b</a>) when you have intermittent claudication and a disease that results in abnormal 
                arterial calcification (for example, Monckeberg's sclerosis or diabetes mellitus) or small vessel disease (for example, diabetes mellitus). 
                These diseases may result in misleadingly high blood pressure readings at the ankle. However, high  blood pressures due to vascular changes related to these diseases seldom occur at the toe level. 
                While the criteria in <a href="#4_12C" title="Section 4.12 - Subsection C">4.12C</a> and <a href="#4_12D" title="Section 4.12 - Subsection D">4.12D</a> are intended primarily for individuals who have a disease 
                causing abnormal arterial calcification or small vessel disease, we may also use them for evaluating anyone with PAD.</p>
            <p id="4_00G8">8. <em>How are toe pressures measured?</em> 
                Toe pressures are measured routinely in most vascular laboratories through one of three methods: most frequently, photoplethysmography; less frequently, plethysmography using strain gauge cuffs; 
                and Doppler ultrasound. Toe pressure can also be measured by using any  blood pressure cuff that fits snugly around the big toe and is neither too tight nor too loose. 
                A neonatal cuff or a cuff designed for use on fingers or toes can be used in the measurement of toe pressure.</p>
            <p id="4_00G9">9. <em>How do we use listing <a href="#4_12" title="Section 4.12">4.12</a> if you have had a peripheral graft?</em> 
                Peripheral grafting serves the  same purpose as coronary grafting; that is, to bypass a narrow or obstructed  arterial segment. If intermittent claudication recurs or persists after  peripheral grafting, 
                we may purchase Doppler studies to assess the flow of blood  through the bypassed vessel and to establish the current severity of the  peripheral arterial impairment. 
                However, if you have had peripheral grafting  done for your PAD, we will not use the findings from before the surgery to assess the current severity of your impairment, 
                although we will consider the severity and duration of your impairment prior to your surgery in making our determination or decision.</p>
            <p id="4_00H"><strong>H.</strong><em> Evaluating  Other Cardiovascular Impairments</em></p>
            <p id="4_00H1">1. <em>How will we evaluate  hypertension?</em> Because <em>hypertension</em> (high blood pressure)  generally causes disability through its effects on other body systems, we will  evaluate it by reference to the specific body system(s) affected (heart, brain,  kidneys, or eyes) when we consider its effects under the listings. We will also  consider any limitations imposed by your hypertension when we assess your  residual functional capacity.</p>
            <p id="4_00H2">2. <em>How will we evaluate  symptomatic congenital heart disease? 
                Congenital heart disease</em> is any abnormality of the heart or the major blood vessels that is present at birth.  Because of improved treatment methods, 
                more children with congenital heart disease are living to adulthood. Although some types of congenital heart disease may be corrected by surgery, many individuals with treated congenital heart disease 
                continue to have problems throughout their lives (symptomatic congenital heart disease). If you have congenital heart disease that results in chronic heart failure with evidence of ventricular dysfunction 
                or in recurrent arrhythmias, we will evaluate your impairment under <a href="#4_02" title="Section 4.02">4.02</a> or <a href="#4_05" title="Section 4.05">4.05</a>.
    Otherwise, we  will evaluate your impairment under <a href="#4_06" title="Section 4.06">4.06</a>.
</p>
            <p id="4_00H3">3. <em>What is  cardiomyopathy and how will we evaluate it? 
                Cardiomyopathy</em> is a disease of the heart muscle. The heart loses its ability to pump blood (heart failure), and in some instances, heart rhythm is disturbed, leading to irregular  heartbeats (arrhythmias). 
                Usually, the exact cause of the muscle damage is  never found (idiopathic cardiomyopathy). There are various types of cardiomyopathy, 
                which fall into two major categories: <em>Ischemic</em> and <em>nonischemic</em> cardiomyopathy. 
                Ischemic cardiomyopathy typically refers to heart muscle damage  that results from coronary artery disease, including heart attacks. Nonischemic cardiomyopathy includes several types: 
                Dilated, hypertrophic, and restrictive.  We will evaluate cardiomyopathy under <a href="#4_02" title="Section 4.02">4.02</a>, <a href="#4_04" title="Section 4.04">4.04</a>, 
                <a href="#4_05" title="Section 4.05">4.05</a>, or <a href="11.00-Neurological-Adult.htm#11_04" title="11.00 Neurological Disorders Page, Section 11.04" target="_blank">11.04</a>, depending on its effects on you.</p>
            <p id="4_00H4">4. <em>How will we evaluate valvular heart disease?</em> We will evaluate valvular heart disease under the listing appropriate for its effect on you. 
                Thus, we may use <a href="#4_02" title="Section 4.02">4.02</a>, <a href="#4_04" title="Section 4.04">4.04</a>, <a href="#4_05" title="Section 4.05">4.05</a>, 
                <a href="#4_06" title="Section 4.06">4.06</a>,or an appropriate neurological listing in <a href="11.00-Neurological-Adult.htm#11_00ff" title="11.00 Neurological Disorders Page, Section 11.00 - Subsection FF" target="_blank">11.00ff</a>.
</p>
            <p id="4_00H5">5. <em>What do we consider when we evaluate heart transplant recipients?</em></p>
            <p id="4_00H5a">a. After your heart  transplant, we will consider you disabled for 1 year following the surgery  because there is a greater likelihood of rejection of the organ and infection  during the first year.</p>
            <p id="4_00H5b">b. However, heart transplant  patients generally meet our definition of disability before they undergo  transplantation. We will determine the onset of your disability based on the  facts in your case.</p>
            <p id="4_00H5c">c. We will not assume that  you became disabled when your name was placed on a transplant waiting list.  This is because you may be placed on a waiting list soon after diagnosis of the  cardiac disorder that may eventually require a transplant. Physicians recognize  that candidates for transplantation often have to wait months or even years  before a suitable donor heart is found, so they place their patients on the  list as soon as permitted.</p>
            <p id="4_00H5d">d. When we do a continuing  disability review to determine whether you are still disabled, we will evaluate  your residual impairment(s), as shown by symptoms, signs,
                and laboratory findings, including any side effects of medication. We will consider any remaining  symptoms, signs, and laboratory findings indicative of cardiac dysfunction in  deciding whether medical improvement
                (as defined in §§ <a href="https://www.ssa.gov/OP_Home/cfr20/404/404-1594.htm" target="_blank" title="Code of Federal Regulations section 404.1594">404.1594</a> 
                and <a href="https://www.ssa.gov/OP_Home/cfr20/416/416-0994.htm" target="_blank" title="Code of Federal Regulations section 416.994">416.994</a>) has occurred.
</p>
            <p id="4_00H6">6. <em>When does an aneurysm  have “dissection not controlled by prescribed treatment,
                ” as required under <a href="#4_10" title="Section 4.10">4.10</a>?</em> An aneurysm (or bulge in the aorta or one of its major branches) 
                is <em>dissecting</em> when the inner lining of the artery begins to separate from the arterial wall. We consider the dissection not controlled when you have persistence of chest  pain due to progression of the dissection,
                an increase in the size of the  aneurysm, or compression of one or more branches of the aorta supplying the  heart, kidneys, brain, or other organs. An aneurysm with dissection can cause  heart failure, 
                renal (kidney) failure, or neurological complications. If you have an aneurysm that does not meet the requirements of <a href="#4_10" title="Section 4.10">4.10</a> and you have one  or more of these associated conditions,
    we will evaluate the condition(s) using  the appropriate listing.
</p>
            <p id="4_00H7">7. <em>What is hyperlipidemia  and how will we evaluate it? Hyperlipidemia</em> is the general term for an  elevation of any or all of the lipids (fats or cholesterol) in the blood; for  example, hypertriglyceridemia, hypercholesterolemia, and hyperlipoproteinemia.  These disorders of lipoprotein metabolism and transport can cause defects  throughout the body. The effects most likely to interfere with function are  those produced by atherosclerosis (narrowing of the arteries) and coronary  artery disease. We will evaluate your lipoprotein disorder by considering its  effects on you.</p>
            <p id="4_00H8">8. <em>What is Marfan syndrome and how will we evaluate it?</em></p>
            <p id="4_00H8a">a. Marfan syndrome is a genetic connective tissue disorder that affects multiple body systems,  including the skeleton, eyes, heart, blood vessels, nervous system, skin, and  lungs. There is no specific laboratory test to diagnose Marfan syndrome. The  diagnosis is generally made by medical history, including family history,  physical examination, including an evaluation of the ratio of arm/leg size to  trunk size, a slit lamp eye examination, and a heart test(s), such as an  echocardiogram. In some cases, a genetic analysis may be useful, but such  analyses may not provide any additional helpful information.</p>
            <p id="4_00H8b">b. The effects of Marfan syndrome can range from mild to severe. In most cases, the disorder progresses as you age. 
                Most individuals with Marfan syndrome have abnormalities associated with the heart and blood vessels. Your heart's mitral valve may leak, causing a  heart murmur. Small leaks may not cause symptoms, 
                but larger ones may cause  shortness of breath, fatigue, and palpitations. Another effect is that the wall  of the aorta may be weakened and abnormally stretch (aortic dilation). 
                This aortic dilation may tear, dissect, or rupture, causing serious heart problems or sometimes sudden death. We will evaluate the manifestations of your Marfan  syndrome under the appropriate body system criteria, 
                such as <a href="#4_10" title="Section 4.10">4.10</a>, or if  necessary, consider the functional limitations imposed by your impairment.</p>
            <p id="4_00I"><strong>I.</strong> <em>Other Evaluation Issues</em> </p>
            <p id="4_00I1">1. <em>What effect does obesity have on the cardiovascular system and how will we evaluate it?</em> Obesity is a medically determinable impairment that is often associated with  disorders of the cardiovascular system. Disturbance of this system can be a  major cause of disability if you have obesity. Obesity may affect the  cardiovascular system because of the increased workload the additional body  mass places on the heart. Obesity may make it harder for the chest and lungs to  expand. This can mean that the respiratory system must work harder to provide  needed oxygen. This in turn would make the heart work harder to pump blood to  carry oxygen to the body. Because the body would be working harder at rest, its  ability to perform additional work would be less than would otherwise be  expected. Thus, the combined effects of obesity with cardiovascular impairments  can be greater than the effects of each of the impairments considered  separately. We must consider any additional and cumulative effects of obesity  when we determine whether you have a severe cardiovascular impairment or a  listing-level cardiovascular impairment (or a combination of impairments that  medically equals the severity of a listed impairment), and when we assess your  residual functional capacity.</p>
            <p id="4_00I2">2. <em>How do we relate treatment to functional status?</em> 
                In general, conclusions about the severity of a cardiovascular impairment cannot be made on the basis of type of treatment rendered or anticipated. 
                The amount of function restored and the time required for improvement after treatment (medical, surgical, or a prescribed program of progressive physical activity) vary with the nature and extent of the disorder,  
                the type of treatment, and other factors. Depending upon the timing of this  treatment in relation to the alleged onset date of disability, 
                we may need to defer evaluation of the impairment for a period of up to 3 months from the date treatment began to permit consideration of treatment effects, 
                unless we can make a determination or decision using the evidence we have. See <a href="#4_00B4" title="Section 4.00 - Subsection B4">4.00B4</a>.</p>
            <p id="4_00I3">3. <em>How do we evaluate impairments that do not meet one of the cardiovascular listings?</em></p>
            <p id="4_00I3a">a. These listings are only examples of common cardiovascular impairments that we consider severe enough to  prevent you from doing any gainful activity. If your severe impairment(s) does  not meet the criteria of any of these listings, we must also consider whether  you have an impairment(s) that satisfies the criteria of a listing in another  body system.</p>
            <p id="4_00I3b">b. If you have a severe medically determinable impairment(s) that does not meet a listing, we will determine whether your impairments(s) medically equals a listing. 
                (See §§ <a href="https://www.ssa.gov/OP_Home/cfr20/404/404-1526.htm" target="_blank" title="Code of Federal Regulations section 404.1526">404.1526</a> 
    and <a href="https://www.ssa.gov/OP_Home/cfr20/416/416-0926.htm" target="_blank" title="Code of Federal Regulations section 416.26">416.926</a>.)
    If you have a severe impairment(s) that does not meet or  medically equal the criteria of a listing, you may or may not have the residual functional capacity to engage in substantial gainful activity.
    Therefore, we  proceed to the fourth and, if necessary, the fifth steps of the sequential evaluation process in
    §§ <a href="https://www.ssa.gov/OP_Home/cfr20/404/404-1520.htm" target="_blank" title="Code of Federal Regulations section 404.1520">404.1520</a>
    and <a href="https://www.ssa.gov/OP_Home/cfr20/416/416-0920.htm" target="_blank" title="Code of Federal Regulations section 416.920">416.920</a>.
    If you are an adult, we use the rules in §§ <a href="https://www.ssa.gov/OP_Home/cfr20/404/404-1594.htm" target="_blank" title="Code of Federal Regulations section 404.1594">404.1594</a>
    or <a href="https://www.ssa.gov/OP_Home/cfr20/416/416-0994.htm" target="_blank" title="Code of Federal Regulations section 416.994">416.994</a>,
    as appropriate, when we decide whether you  continue to be disabled.
</p>
            <p><b><a href="#Top" class="seventypercent">Back to Top</a></b></p>
            <p align="left" id="4_01"><b>4.01 
              Category of Impairments, Cardiovascular System</b></p>
            <p align="left" id="4_02"><b>4.02<i> Chronic heart failure </i></b>while on a regimen of  prescribed treatment, with symptoms and signs described in <a href="#4_00D2" title="Section 4.00 - Subsection D2">4.00D2</a>. 
                The required  level of severity for this impairment is met when the requirements in <em>both  A and B</em> are satisfied.</p>
            <p id="4_02A"><strong>A.</strong> Medically documented  presence of one of the following:</p>
            <p id="4_02A1">1. Systolic failure (see <a href="#4_00D1ai" title="Section 4.00 - Subsection D1ai">4.00D1a(i)</a>),
    with left ventricular end diastolic dimensions greater than 6.0 cm  or ejection fraction of 30 percent or less during a period of stability (not  during an episode of acute heart failure); or
</p>
            <p id="4_02A2">2. Diastolic failure (see <a href="#4_00D1aii" title="Section 4.00 - Subsection D1aii">4.00D1a(ii)</a>),
    with left ventricular posterior wall plus septal thickness totaling 2.5 cm or greater on imaging, with an enlarged left atrium greater than or equal to 4.5 cm, with normal or elevated ejection fraction during a period of stability (not during an episode of acute heart failure);
</p>
            <p>AND</p>
            <p id="4_02B"><strong>B.</strong> Resulting in one of the  following:</p>
            <p id="4_02B1">1. Persistent symptoms of heart failure which very seriously limit the ability to independently initiate,  sustain, or complete activities of daily living in an individual for whom an  MC, preferably one experienced in the care of patients with cardiovascular  disease, has concluded that the performance of an exercise test would present a  significant risk to the individual; or</p>
            
            <p id="4_02B2">2. Three or more separate episodes of acute congestive heart failure within a consecutive 12-month period 
                (see <a href="#4_00A3e" title="Section 4.00 - Subsection A3e">4.00A3e</a>), with evidence of fluid retention 
    (see <a href="#4_00D2bii" title="Section 4.00 - Subsection D2b(ii)">4.00D2b(ii)</a>) from clinical  and imaging assessments at the time of the episodes,
    requiring acute extended physician intervention such as hospitalization or emergency room treatment for  12 hours or more,
    separated by periods of stabilization (see <a href="#4_00D4c" title="Section 4.00 - Subsection D4c">4.00D4c</a>); or
</p>
            
            <p id="4_02B3">3. Inability to perform on an exercise tolerance test at a workload equivalent to 5 METs or less due to:</p>
            
            <p id="4_02B3a">a. Dyspnea, fatigue, palpitations, or chest discomfort; or</p>
            
            <p id="4_02B3b">b. Three or more consecutive premature ventricular contractions (ventricular tachycardia), or increasing  frequency of ventricular ectopy with at least 6 premature ventricular  contractions per minute; or</p>
            
            <p id="4_02B3c">c. Decrease of 10 mm Hg or more in systolic pressure below the baseline systolic blood pressure or the  preceding systolic pressure measured during exercise 
                (see <a href="#4_00D4d" title="Section 4.00 - Subsection D4d">4.00D4d</a>) due to left  ventricular dysfunction, despite an increase in workload; or</p>
            
            <p id="4_02B3d">d. Signs attributable to inadequate cerebral perfusion, such as ataxic gait or mental confusion.</p>
            <p><b><a href="#Top" class="seventypercent">Back to Top</a></b></p>
            <p align="left" id="4_04"><b><i>4.04
              Ischemic heart disease</i></b>, with symptoms due to myocardial ischemia, 
              as described in <a href="#4_00E3" title="Section 4.00 - Subsection E3">4.00E3</a>-<a href="#4_00E7" title="Section 4.00 - Subsection E7">4.00E7</a>,
    while on a regimen  of prescribed treatment (see <a href="#4_00B3" title="Section 4.00 - Subsection B3">4.00B3</a> if there is no regimen of prescribed  treatment), with one of the following:
</p>
            <p id="4_04A"><strong>A.</strong> Sign-or symptom-limited exercise tolerance test demonstrating at least one of the following manifestations at a workload equivalent to 5 METs or less:</p>
            
            <p id="4_04A1">1. Horizontal or downsloping  depression, in the absence of digitalis glycoside treatment or hypokalemia, of  the ST segment of at least −0.10 millivolts (−1.0 mm) in at least 3 consecutive  complexes that are on a level baseline in any lead other than a VR, and  depression of at least −0.10 millivolts lasting for at least 1 minute of  recovery; or</p>
            
            <p id="4_04A2">2. At least 0.1 millivolt (1  mm) ST elevation above resting baseline in non-infarct leads during both  exercise and 1 or more minutes of recovery; or</p>
            
            <p id="4_04A3">3. Decrease of 10 mm Hg or more in systolic pressure below the baseline blood pressure or the preceding  systolic pressure measured during exercise 
            (see <a href="#4_00E9e" title="Section 4.00 - Subsection E9e">4.00E9e</a>) due to left ventricular dysfunction, despite an increase in workload; or</p>
            
            <p id="4_04A4">4. Documented ischemia at an  exercise level equivalent to 5 METs or less on appropriate medically acceptable imaging, such as radionuclide perfusion scans or stress echocardiography. </p>
            
            <p>OR</p>
            <p id="4_04B"><strong>B.</strong> Three separate ischemic episodes, each requiring revascularization or not amenable to revascularization  
                (see <a href="#4_00E9f" title="Section 4.00 - Subsection E9f">4.00E9f</a>), within a consecutive 12-month period (see <a href="#4_00A3e" title="Section 4.00 - Subsection A3e">4.00A3e</a>). </p>
            <p>OR</p>
            <p id="4_04C"><strong>C.</strong> Coronary artery disease,  demonstrated by angiography (obtained independent of Social Security disability  evaluation) or other appropriate medically acceptable imaging, and in the  absence of a timely exercise tolerance test or a timely normal drug-induced  stress test, an MC, preferably one experienced in the care of patients with  cardiovascular disease, has concluded that performance of exercise tolerance  testing would present a significant risk to the individual, with both 1 and 2:</p>
            <p id="4_04C1">1. Angiographic evidence  showing:</p>
            
            <p id="4_04C1a">a. 50 percent or more  narrowing of a nonbypassed left main coronary artery; or</p>
            
            <p id="4_04C1b">b. 70 percent or more  narrowing of another nonbypassed coronary artery; or</p>
            
            <p id="4_04C1c">c. 50 percent or more  narrowing involving a long (greater than 1 cm) segment of a nonbypassed  coronary artery; or</p>
            
            <p id="4_04C1d">d. 50 percent or more narrowing  of at least two nonbypassed coronary arteries; or</p>
            
            <p id="4_04C1e">e. 70 percent or more  narrowing of a bypass graft vessel; and</p>
            
            <p id="4_04C2">2. Resulting in very serious  limitations in the ability to independently initiate, sustain, or complete  activities of daily living.</p>
            <p><b><a href="#Top" class="seventypercent">Back to Top</a></b></p>
            <p align="left" id="4_05"><b><i>4.05 
              Recurrent arrhythmias</i></b>, not related to reversible  causes, such as electrolyte abnormalities or digitalis glycoside or  antiarrhythmic drug toxicity, 
                resulting in uncontrolled (see <a href="#4_00A3f" title="Section 4.00 - Subsection A3f">4.00A3f</a>),  
                recurrent (see <a href="#4_00A3c" title="Section 4.00 - Subsection A3c">4.00A3c</a>) episodes of cardiac syncope or near syncope (see  <a href="#4_00F3b" title="Section 4.00 - Subsection F3b">4.00F3b</a>), 
                despite prescribed treatment(see <a href="#4_00B3" title="Section 4.00 - Subsection B3">4.00B3</a> if there is no prescribed  treatment), and documented by resting or ambulatory (Holter)  electrocardiography,
    or by other appropriate medically acceptable testing,
    coincident with the occurrence of syncope or near syncope (see <a href="#4_00F3" title="Section 4.00 - Subsection F3">4.00F3c</a>).
</p>
            <p align="left"><b><a href="#Top" class="seventypercent">Back to Top</a></b></p>
            <p id="4_06"><b><i>4.06 
              Symptomatic congenital heart disease</i></b><i> 
              </i>(cyanotic or acyanotic),  documented by appropriate medically acceptable imaging (see <a href="#4_00A3d" title="Section 4.00 - Subsection A3d">4.00A3d</a>) or cardiac  catheterization, with one of the following:</p>
            <p id="4_06A"><strong>A.</strong> Cyanosis at rest, and:</p>
            
            <p id="4_06A1">1. Hematocrit of 55 percent  or greater; or</p>
            
            <p id="4_06A2">2. Arterial O2  saturation of less than 90 percent in room air, or resting arterial PO2  of 60 Torr or less. </p>
             
            <p>OR</p>
            
            <p id="4_06B"><strong>B.</strong> Intermittent  right-to-left shunting resulting in cyanosis on exertion (e.g., Eisenmenger's  physiology) and with arterial PO2 of 60 Torr or less at a workload  equivalent to 5 METs or less. </p>
            
            <p>OR</p>
            
            <p id="4_06C"><strong>C.</strong> Secondary pulmonary  vascular obstructive disease with pulmonary arterial systolic pressure elevated  to at least 70 percent of the systemic arterial systolic pressure.</p>
            <p><b><a href="#Top" class="seventypercent">Back to Top</a></b></p>
            <p align="left" id="4_09"><b><i>4.09 
              Heart transplant</i></b>. Consider under a disability for 1 year  following surgery; thereafter, evaluate residual impairment under the  appropriate listing.</p>
            <p align="left"><b><a href="#Top" class="seventypercent">Back to Top</a></b></p>
            <p align="left" id="4_10"><b><i> 4.10
              Aneurysm of aorta or major branches</i></b>, due to any cause (e.g.,  atherosclerosis, cystic medial necrosis, Marfan syndrome, trauma), 
            demonstrated  by appropriate medically acceptable imaging, with dissection not controlled by prescribed treatment (see <a href="#4_00H6" title="Section 4.00 - Subsection H6">4.00H6</a>).</p>
            <p align="left"><b><a href="#Top" class="seventypercent">Back to Top</a></b></p>
            <p id="4_11"><strong><em>4.11</em></strong><strong><em> Chronic venous insufficiency</em></strong><strong> </strong>of a lower extremity with  incompetency or obstruction of the deep venous system and one of the following:</p>
            <p id="4_11A"><strong>A.</strong> Extensive brawny edema  (see <a href="#4_00G3" title="Section 4.00 - Subsection G3">4.00G3</a>) 
                involving at least two-thirds of the leg between the ankle and knee or the distal one-third of the lower extremity between the ankle and hip. </p>
            
            <p>OR</p>
            
            <p id="4_11B"><strong>B.</strong> Superficial varicosities, stasis dermatitis, and either recurrent ulceration or persistent ulceration that has not healed following at least 3 months of prescribed treatment.</p>
            <p><b><a href="#Top" class="seventypercent">Back to Top</a></b></p>
            <p align="left" id="4_12"><strong><em>4.12</em></strong><strong><em> Peripheral  arterial disease</em></strong>, 
                as determined by appropriate medically acceptable imaging (see <a href="#4_00A3d" title="Section 4.00 - Subsection A3d">4.00A3d</a>, 
                                                                                   <a href="#4_00G2" title="Section 4.00 - Subsection G2">4.00G2</a>, 
                                                                                       <a href="#4_00G5" title="Section 4.00 - Subsection G5">4.00G5</a>, and  
                                                                                           <a href="#4_00G6" title="Section 4.00 - Subsection G6">4.00G6</a>), causing intermittent claudication 
                                                                                               (see <a href="#4_00G1" title="Section 4.00 - Subsection G1">4.00G1</a>) and one of the  following:</p>
            <p id="4_12A"><strong>A.</strong> Resting ankle/brachial  systolic blood pressure ratio of less than 0.50. </p>
            
            <p>OR</p>
            
            <p id="4_12B"><strong>B.</strong> Decrease in systolic  blood pressure at the ankle on exercise 
            (see <a href="#4_00G7a" title="Section 4.00 - Subsection G7a">4.00G7a</a> and <a href="#4_00C16" title="Section 4.00 - Subsection C16">4.00C16</a>-<a href="#4_00C17" title="Section 4.00 - Subsection C17">4.00C17</a>) 
                of 50 percent or more of pre-exercise level and requiring 10 minutes or more to return to pre-exercise level. </p>
            
            <p>OR</p>
            
            <p id="4_12C"><strong>C.</strong> Resting toe systolic  pressure of less than 30 mm Hg 
            (see <a href="#4_00G7c" title="Section 4.00 - Subsection G7c">4.00G7c</a> and <a href="#4_00G8" title="Section 4.00 - Subsection G8">4.00G8</a>). </p>
            
            <p>OR</p>
            
            <p id="4_12D"><strong>D.</strong> Resting toe/brachial  systolic blood pressure ratio of less than 0.40 (see <a href="#4_00G7c" title="Section 4.00 - Subsection G7c">4.00G7c</a>).</p>
            <p><b><a href="#Top" class="seventypercent">Back to Top</a></b></p>
            
 </article><!-- END SECOND INNER COLUMN -->
 
 </div><!-- END GRID-->

</article><!-- END SECOND COLUMN -->

</div><!-- END GRID-->

    </section>
  </main>
  <!-- FOOTER -->
  <ssa-footer class="print-dn"></ssa-footer><script src="https://www.ssa.gov/legacy/components/dist/ssa-footer.js"></script>
  <!-- SCRIPTS -->
  <script src="/framework/js/ssa.firefly.body.js"></script><a class="js-btt" href="#" title="Back to Top"></a>


</body></html>